https://trial.medpath.com/news/vaping-addiction-drug-developer-achieve-to-sell-up-to-50-million-of-stock-kursiv-kz 2024-09-30T13:33:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vaping-addiction-drug-developer-achieve-to-sell-up-to-50-million-of-stock-kursiv-kz 2024-09-30T13:33:20+00:00 weekly 0.7 https://trial.medpath.com/news/bay-area-surfer-scientologist-and-billionaire-is-tackling-one-of-medicine-s-toughest-problems 2024-09-30T13:19:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bay-area-surfer-scientologist-and-billionaire-is-tackling-one-of-medicine-s-toughest-problems 2024-09-30T13:19:57+00:00 weekly 0.7 https://trial.medpath.com/news/accelerate-diagnostics-announces-fda-clearance-of-its-accelerate-arctm-system 2024-09-30T13:19:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/accelerate-diagnostics-announces-fda-clearance-of-its-accelerate-arctm-system 2024-09-30T13:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/catching-up-with-synchron-s-tom-oxley-on-the-path-to-a-pivotal-trial 2024-09-30T13:16:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/catching-up-with-synchron-s-tom-oxley-on-the-path-to-a-pivotal-trial 2024-09-30T13:16:31+00:00 weekly 0.7 https://trial.medpath.com/news/study-examining-use-of-nalmefene-hci-injection-for-opioid-overdose-reversal-in 2024-09-30T13:13:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-examining-use-of-nalmefene-hci-injection-for-opioid-overdose-reversal-in 2024-09-30T13:13:35+00:00 weekly 0.7 https://trial.medpath.com/news/bioai-arbele-partner-to-advance-predictive-ai-models-in-oncology-clinical-trials 2024-09-30T13:11:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioai-arbele-partner-to-advance-predictive-ai-models-in-oncology-clinical-trials 2024-09-30T13:11:17+00:00 weekly 0.7 https://trial.medpath.com/news/penn-state-college-of-medicine-beat-childhood-cancer-research-consortium-and-four 2024-09-30T13:10:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/penn-state-college-of-medicine-beat-childhood-cancer-research-consortium-and-four 2024-09-30T13:10:05+00:00 weekly 0.7 https://trial.medpath.com/news/madrigal-pharmaceuticals-announces-publication-of-positive-health-related-quality-of-life 2024-09-30T13:05:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/madrigal-pharmaceuticals-announces-publication-of-positive-health-related-quality-of-life 2024-09-30T13:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/inmune-bio-inc-completes-enrollment-for-phase-2-trial-in-early-alzheimer-s-disease 2024-09-30T13:05:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inmune-bio-inc-completes-enrollment-for-phase-2-trial-in-early-alzheimer-s-disease 2024-09-30T13:05:41+00:00 weekly 0.7 https://trial.medpath.com/news/could-we-prevent-asthma-in-young-allergic-children-boston-children-s-answers 2024-09-30T13:05:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-we-prevent-asthma-in-young-allergic-children-boston-children-s-answers 2024-09-30T13:05:12+00:00 weekly 0.7 https://trial.medpath.com/news/medicinova-to-support-nih-funded-expanded-access-clinical-globenewswire 2024-09-30T13:03:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicinova-to-support-nih-funded-expanded-access-clinical-globenewswire 2024-09-30T13:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/mitsubishi-tanabe-pharma-america-presents-open-label-extension-outcomes-and-pr-newswire 2024-09-30T13:02:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mitsubishi-tanabe-pharma-america-presents-open-label-extension-outcomes-and-pr-newswire 2024-09-30T13:02:41+00:00 weekly 0.7 https://trial.medpath.com/news/nanoviricides-prepares-for-phase-ii-trials-for-antiviral-nv-387-nyse-a-nnvc 2024-09-30T13:01:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanoviricides-prepares-for-phase-ii-trials-for-antiviral-nv-387-nyse-a-nnvc 2024-09-30T13:01:37+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-the-fight-against-superbacteria-by-a-hungarian-research-team 2024-09-30T12:47:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-the-fight-against-superbacteria-by-a-hungarian-research-team 2024-09-30T12:47:42+00:00 weekly 0.7 https://trial.medpath.com/news/advancing-clinical-basic-clinical-research-exploring-novel-immunotargets-for-ovarian-cancer 2024-09-30T12:45:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancing-clinical-basic-clinical-research-exploring-novel-immunotargets-for-ovarian-cancer 2024-09-30T12:45:30+00:00 weekly 0.7 https://trial.medpath.com/news/altimmune-completes-enrollment-in-phase-2b-impact-trial-of-pemvidutide-in-metabolic 2024-09-30T12:41:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/altimmune-completes-enrollment-in-phase-2b-impact-trial-of-pemvidutide-in-metabolic 2024-09-30T12:41:42+00:00 weekly 0.7 https://trial.medpath.com/news/windtree-announces-positive-phase-2b-topline-clinical-globenewswire 2024-09-30T12:36:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/windtree-announces-positive-phase-2b-topline-clinical-globenewswire 2024-09-30T12:36:30+00:00 weekly 0.7 https://trial.medpath.com/news/new-3-year-skeletal-dynamics-data-for-adults-with-hypoparathyroidism-treated-with-stock-titan 2024-09-30T12:34:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-3-year-skeletal-dynamics-data-for-adults-with-hypoparathyroidism-treated-with-stock-titan 2024-09-30T12:34:52+00:00 weekly 0.7 https://trial.medpath.com/news/nervgen-pharma-provides-update-on-phase-1b-2a-clinical-trial-of-nvg-291-in-spinal-cord-injury 2024-09-30T12:34:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nervgen-pharma-provides-update-on-phase-1b-2a-clinical-trial-of-nvg-291-in-spinal-cord-injury 2024-09-30T12:34:47+00:00 weekly 0.7 https://trial.medpath.com/news/aeon-biopharma-announces-positive-outcome-from-fda-biosimilar-advisory-meeting 2024-09-30T12:22:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aeon-biopharma-announces-positive-outcome-from-fda-biosimilar-advisory-meeting 2024-09-30T12:22:50+00:00 weekly 0.7 https://trial.medpath.com/news/perfluorohexyloctane-ophthalmic-solution-for-dry-eye-disease-pooled-analysis-of-two-phase 2024-09-30T12:18:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/perfluorohexyloctane-ophthalmic-solution-for-dry-eye-disease-pooled-analysis-of-two-phase 2024-09-30T12:18:17+00:00 weekly 0.7 https://trial.medpath.com/news/precision-biosciences-submits-first-clinical-trial-applications-to-initiate-phase-1-trial-biospace 2024-09-30T12:17:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precision-biosciences-submits-first-clinical-trial-applications-to-initiate-phase-1-trial-biospace 2024-09-30T12:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/the-targeted-pulse-nkt2152-sparks-excitement-in-rcc-amivantamab-chemotherapy 2024-09-30T12:17:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-targeted-pulse-nkt2152-sparks-excitement-in-rcc-amivantamab-chemotherapy 2024-09-30T12:17:00+00:00 weekly 0.7 https://trial.medpath.com/news/adaptive-research-announces-it-has-begun-enrolling-patients-in-aribio-s-phase-3-polaris 2024-09-30T12:16:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adaptive-research-announces-it-has-begun-enrolling-patients-in-aribio-s-phase-3-polaris 2024-09-30T12:16:17+00:00 weekly 0.7 https://trial.medpath.com/news/calidi-biotherapeutics-announces-fda-clearance-of-the-globenewswire 2024-09-30T12:14:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/calidi-biotherapeutics-announces-fda-clearance-of-the-globenewswire 2024-09-30T12:14:32+00:00 weekly 0.7 https://trial.medpath.com/news/neurobo-pharmaceuticals-announces-positive-top-line-data-from-the-sad-part-1-of-its 2024-09-30T12:04:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurobo-pharmaceuticals-announces-positive-top-line-data-from-the-sad-part-1-of-its 2024-09-30T12:04:36+00:00 weekly 0.7 https://trial.medpath.com/news/family-heart-foundation-launches-free-at-home-lipid-screening-program-to-combat-cardiovascular-disease 2024-09-30T12:00:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/family-heart-foundation-launches-free-at-home-lipid-screening-program-to-combat-cardiovascular-disease 2024-09-30T12:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/dana-farber-cancer-institute-raises-more-than-2-billion-in-record-breaking-fundraising 2024-09-30T11:43:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dana-farber-cancer-institute-raises-more-than-2-billion-in-record-breaking-fundraising 2024-09-30T11:43:22+00:00 weekly 0.7 https://trial.medpath.com/news/geneditbio-secures-strategic-investment-from-gobi-partners-gba-to-accelerate 2024-09-30T11:42:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/geneditbio-secures-strategic-investment-from-gobi-partners-gba-to-accelerate 2024-09-30T11:42:35+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-completes-enrollment-of-fortify-phase-3-globenewswire 2024-09-30T11:33:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-completes-enrollment-of-fortify-phase-3-globenewswire 2024-09-30T11:33:37+00:00 weekly 0.7 https://trial.medpath.com/news/biohaven-initiates-pivotal-trial-of-novel-investigational-drug-for-treatment-of-migraine 2024-09-30T11:32:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biohaven-initiates-pivotal-trial-of-novel-investigational-drug-for-treatment-of-migraine 2024-09-30T11:32:34+00:00 weekly 0.7 https://trial.medpath.com/news/national-institutes-of-health-study-finds-no-reliable-biomarkers-exist-for-long-covid 2024-09-30T11:29:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/national-institutes-of-health-study-finds-no-reliable-biomarkers-exist-for-long-covid 2024-09-30T11:29:08+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-announces-first-participant-dosed-in-pivotal-phase-3-trial-of-investigational 2024-09-30T11:17:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-announces-first-participant-dosed-in-pivotal-phase-3-trial-of-investigational 2024-09-30T11:17:12+00:00 weekly 0.7 https://trial.medpath.com/news/2-minute-medicine-rewind-september-30-2024 2024-09-30T11:10:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2-minute-medicine-rewind-september-30-2024 2024-09-30T11:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-stocks-facing-fda-decision-in-october-2024-rttnews 2024-09-30T11:05:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotech-stocks-facing-fda-decision-in-october-2024-rttnews 2024-09-30T11:05:21+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-pharmaceuticals-announces-participation-in-endpoints-globenewswire 2024-09-30T11:01:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-announces-participation-in-endpoints-globenewswire 2024-09-30T11:01:41+00:00 weekly 0.7 https://trial.medpath.com/news/self-management-support-program-delivered-in-the-sub-acute-phase-after-traumatic-injury 2024-09-30T10:39:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/self-management-support-program-delivered-in-the-sub-acute-phase-after-traumatic-injury 2024-09-30T10:39:05+00:00 weekly 0.7 https://trial.medpath.com/news/nanoviricides-inc-has-filed-its-annual-report-broad-spectrum-antiviral-nv-387-stock-titan 2024-09-30T10:35:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanoviricides-inc-has-filed-its-annual-report-broad-spectrum-antiviral-nv-387-stock-titan 2024-09-30T10:35:48+00:00 weekly 0.7 https://trial.medpath.com/news/primary-endpoint-met-in-phase-3-comparative-clinical-study-of-perjeta-r-pertuzumab 2024-09-30T10:18:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/primary-endpoint-met-in-phase-3-comparative-clinical-study-of-perjeta-r-pertuzumab 2024-09-30T10:18:55+00:00 weekly 0.7 https://trial.medpath.com/news/grunenthal-appoints-dr-jan-adams-as-chief-commercial-officer 2024-09-30T10:14:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grunenthal-appoints-dr-jan-adams-as-chief-commercial-officer 2024-09-30T10:14:20+00:00 weekly 0.7 https://trial.medpath.com/news/pharmaust-limited-issues-new-shares-advances-als-treatment-tipranks-com 2024-09-30T09:34:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmaust-limited-issues-new-shares-advances-als-treatment-tipranks-com 2024-09-30T09:34:58+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-approves-yuvanci-r-single-tablet-globenewswire 2024-09-30T09:16:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-commission-approves-yuvanci-r-single-tablet-globenewswire 2024-09-30T09:16:31+00:00 weekly 0.7 https://trial.medpath.com/news/synthetic-thc-may-calm-agitation-in-alzheimer-s-patients 2024-09-30T09:09:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/synthetic-thc-may-calm-agitation-in-alzheimer-s-patients 2024-09-30T09:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/role-of-the-screening-with-coronary-computed-tomography-angiography-on-lipid-trials-journal 2024-09-30T08:34:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/role-of-the-screening-with-coronary-computed-tomography-angiography-on-lipid-trials-journal 2024-09-30T08:34:37+00:00 weekly 0.7 https://trial.medpath.com/news/a-decade-of-pd-1-inhibitors-keytruda-and-opdivo-transform-global-cancer-treatment-landscape 2024-09-30T07:59:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-decade-of-pd-1-inhibitors-keytruda-and-opdivo-transform-global-cancer-treatment-landscape 2024-09-30T07:59:04+00:00 weekly 0.7 https://trial.medpath.com/news/medicines-regulators-weigh-hope-and-hype-with-new-alzheimer-s-drugs-swissinfo 2024-09-30T07:47:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicines-regulators-weigh-hope-and-hype-with-new-alzheimer-s-drugs-swissinfo 2024-09-30T07:47:19+00:00 weekly 0.7 https://trial.medpath.com/news/doer-biologics-announces-first-patient-dosed-in-phase-2-study-of-dr10624-for-treatment 2024-09-30T07:19:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/doer-biologics-announces-first-patient-dosed-in-phase-2-study-of-dr10624-for-treatment 2024-09-30T07:19:07+00:00 weekly 0.7 https://trial.medpath.com/news/sifi-announces-allowance-of-patent-on-polihexanide-for-europe-and-commercial-launch-of 2024-09-30T07:01:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sifi-announces-allowance-of-patent-on-polihexanide-for-europe-and-commercial-launch-of 2024-09-30T07:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/identifying-biomarkers-for-treatment-of-uveal-melanoma-by-t-cell-engager-using-a-qsp-model 2024-09-30T06:37:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/identifying-biomarkers-for-treatment-of-uveal-melanoma-by-t-cell-engager-using-a-qsp-model 2024-09-30T06:37:57+00:00 weekly 0.7 https://trial.medpath.com/news/ai-solutions-show-promise-in-combating-pharmacist-burnout-and-enhancing-patient-care 2024-09-30T06:36:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-solutions-show-promise-in-combating-pharmacist-burnout-and-enhancing-patient-care 2024-09-30T06:36:29+00:00 weekly 0.7 https://trial.medpath.com/news/modalis-therapeutics-fda-grants-rare-pediatric-disease-designation-to-mdl-101-for-the 2024-09-30T06:24:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/modalis-therapeutics-fda-grants-rare-pediatric-disease-designation-to-mdl-101-for-the 2024-09-30T06:24:27+00:00 weekly 0.7 https://trial.medpath.com/news/modalis-therapeutics-fda-grants-rare-pediatric-disease-designation-to-mdl-101-for-the 2024-09-30T06:21:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/modalis-therapeutics-fda-grants-rare-pediatric-disease-designation-to-mdl-101-for-the 2024-09-30T06:21:47+00:00 weekly 0.7 https://trial.medpath.com/news/pharmacokinetics-and-pharmacogenomics-of-ribociclib-in-black-patients-with-metastatic 2024-09-30T06:16:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmacokinetics-and-pharmacogenomics-of-ribociclib-in-black-patients-with-metastatic 2024-09-30T06:16:25+00:00 weekly 0.7 https://trial.medpath.com/news/photocure-partner-asieris-unveils-cevira-apl-1702-phase-iii-subgroup-analysis-by-age 2024-09-30T06:05:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/photocure-partner-asieris-unveils-cevira-apl-1702-phase-iii-subgroup-analysis-by-age 2024-09-30T06:05:07+00:00 weekly 0.7 https://trial.medpath.com/news/verona-pharma-to-present-six-analyses-of-the-phase-3-enhance-studies-in-copd-at-chest-2024 2024-09-30T06:03:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verona-pharma-to-present-six-analyses-of-the-phase-3-enhance-studies-in-copd-at-chest-2024 2024-09-30T06:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/lexaria-receives-independent-review-board-approval-to-begin-human-pilot-study-3 2024-09-30T06:03:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexaria-receives-independent-review-board-approval-to-begin-human-pilot-study-3 2024-09-30T06:03:09+00:00 weekly 0.7 https://trial.medpath.com/news/cinclus-pharma-completes-imp-manufacturing-for-phase-iii-marketscreener 2024-09-30T05:56:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cinclus-pharma-completes-imp-manufacturing-for-phase-iii-marketscreener 2024-09-30T05:56:24+00:00 weekly 0.7 https://trial.medpath.com/news/akeso-s-cadonilimab-receives-second-indication-approval-from-nmpa-for-first-line 2024-09-30T05:48:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akeso-s-cadonilimab-receives-second-indication-approval-from-nmpa-for-first-line 2024-09-30T05:48:12+00:00 weekly 0.7 https://trial.medpath.com/news/veteran-tennessee-pharmacist-reflects-on-45-years-of-community-service-and-industry-evolution 2024-09-30T05:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/veteran-tennessee-pharmacist-reflects-on-45-years-of-community-service-and-industry-evolution 2024-09-30T05:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/experts-highlight-critical-treatment-gaps-in-metastatic-colorectal-cancer-management 2024-09-30T05:00:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-highlight-critical-treatment-gaps-in-metastatic-colorectal-cancer-management 2024-09-30T05:00:50+00:00 weekly 0.7 https://trial.medpath.com/news/closer-to-us-commercialisation-ebr-achieves-major-fda-milestone-stockhead 2024-09-30T05:00:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/closer-to-us-commercialisation-ebr-achieves-major-fda-milestone-stockhead 2024-09-30T05:00:33+00:00 weekly 0.7 https://trial.medpath.com/news/ai-revolutionizes-healthcare-economics-transforming-clinical-trials-and-value-assessment 2024-09-30T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-revolutionizes-healthcare-economics-transforming-clinical-trials-and-value-assessment 2024-09-30T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-action-alert-biofrontera-bms-and-zealand-biospace 2024-09-30T04:21:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-action-alert-biofrontera-bms-and-zealand-biospace 2024-09-30T04:21:48+00:00 weekly 0.7 https://trial.medpath.com/news/jeil-pharm-launches-jaqbo-its-1st-in-house-drug-in-korea-s-1-billion-peptic-ulcer-market 2024-09-30T03:57:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jeil-pharm-launches-jaqbo-its-1st-in-house-drug-in-korea-s-1-billion-peptic-ulcer-market 2024-09-30T03:57:24+00:00 weekly 0.7 https://trial.medpath.com/news/duke-nus-study-proposes-new-heart-failure-treatment-targeting-abnormal-hormone-activity 2024-09-30T03:14:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/duke-nus-study-proposes-new-heart-failure-treatment-targeting-abnormal-hormone-activity 2024-09-30T03:14:56+00:00 weekly 0.7 https://trial.medpath.com/news/percheron-therapeutics-completes-toxicology-study-for-avicursen-ahead-of-us-fda-discussions 2024-09-30T02:42:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/percheron-therapeutics-completes-toxicology-study-for-avicursen-ahead-of-us-fda-discussions 2024-09-30T02:42:28+00:00 weekly 0.7 https://trial.medpath.com/news/valerio-therapeutics-expands-antibody-development-capabilities-with-emglev-therapeutics-acquisition 2024-09-30T02:38:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/valerio-therapeutics-expands-antibody-development-capabilities-with-emglev-therapeutics-acquisition 2024-09-30T02:38:12+00:00 weekly 0.7 https://trial.medpath.com/news/up-manila-researchers-unveil-promising-ampalaya-tablet-for-type-2-diabetes 2024-09-30T02:07:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/up-manila-researchers-unveil-promising-ampalaya-tablet-for-type-2-diabetes 2024-09-30T02:07:59+00:00 weekly 0.7 https://trial.medpath.com/news/mesoblast-to-raise-50m-from-top-shareholder-for-product-launch-capital-brief 2024-09-30T00:58:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mesoblast-to-raise-50m-from-top-shareholder-for-product-launch-capital-brief 2024-09-30T00:58:56+00:00 weekly 0.7 https://trial.medpath.com/news/cutia-therapeutics-completes-phase-ii-trial-tipranks-com 2024-09-30T00:11:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cutia-therapeutics-completes-phase-ii-trial-tipranks-com 2024-09-30T00:11:13+00:00 weekly 0.7 https://trial.medpath.com/news/medidata-clinches-two-excellence-awards-for-innovative-clinical-trial-solutions 2024-09-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medidata-clinches-two-excellence-awards-for-innovative-clinical-trial-solutions 2024-09-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/irlab-completes-patient-enrollment-in-phase-iib-study-of-pirepemat-for-parkinson-s-disease 2024-09-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/irlab-completes-patient-enrollment-in-phase-iib-study-of-pirepemat-for-parkinson-s-disease 2024-09-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merus-announces-fda-approval-of-bizengri-r 2024-09-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merus-announces-fda-approval-of-bizengri-r 2024-09-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/histone-deacetylase-inhibition-enhances-extracellular-vesicles-from-muscle-to-promote 2024-09-29T23:48:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/histone-deacetylase-inhibition-enhances-extracellular-vesicles-from-muscle-to-promote 2024-09-29T23:48:16+00:00 weekly 0.7 https://trial.medpath.com/news/initial-results-of-a-phase-2-trial-of-stereotactic-body-radiation-therapy-hormone-androgen 2024-09-29T23:27:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/initial-results-of-a-phase-2-trial-of-stereotactic-body-radiation-therapy-hormone-androgen 2024-09-29T23:27:21+00:00 weekly 0.7 https://trial.medpath.com/news/bladder-adjuvant-radiotherapy-bart-acute-and-late-toxicity-from-a-phase-iii-multicenter 2024-09-29T23:27:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bladder-adjuvant-radiotherapy-bart-acute-and-late-toxicity-from-a-phase-iii-multicenter 2024-09-29T23:27:19+00:00 weekly 0.7 https://trial.medpath.com/news/astro-2024-post-prostatectomy-linac-based-ultrahypofractionated-radiotherapy-for-urotoday 2024-09-29T23:27:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astro-2024-post-prostatectomy-linac-based-ultrahypofractionated-radiotherapy-for-urotoday 2024-09-29T23:27:16+00:00 weekly 0.7 https://trial.medpath.com/news/astro-2024-integrating-novel-therapeutics-with-trimodal-therapy-tmt-urotoday 2024-09-29T23:27:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astro-2024-integrating-novel-therapeutics-with-trimodal-therapy-tmt-urotoday 2024-09-29T23:27:14+00:00 weekly 0.7 https://trial.medpath.com/news/astro-2024-the-space-time-continuum-in-metastatic-castration-sensitive-prostate-cancer 2024-09-29T23:27:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astro-2024-the-space-time-continuum-in-metastatic-castration-sensitive-prostate-cancer 2024-09-29T23:27:13+00:00 weekly 0.7 https://trial.medpath.com/news/the-alarm-s-mike-peters-says-it-s-incredible-as-he-issues-huge-cancer-update-the-mirror 2024-09-29T23:12:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-alarm-s-mike-peters-says-it-s-incredible-as-he-issues-huge-cancer-update-the-mirror 2024-09-29T23:12:15+00:00 weekly 0.7 https://trial.medpath.com/news/potential-of-device-assisted-therapy-for-advanced-stage-parkinson-disease-david-devos-md-phd 2024-09-29T23:03:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/potential-of-device-assisted-therapy-for-advanced-stage-parkinson-disease-david-devos-md-phd 2024-09-29T23:03:30+00:00 weekly 0.7 https://trial.medpath.com/news/blockchain-technology-emerges-as-key-weapon-against-200b-counterfeit-drug-market 2024-09-29T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blockchain-technology-emerges-as-key-weapon-against-200b-counterfeit-drug-market 2024-09-29T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/people-who-experience-side-effects-from-cranial-radiation-therapy-may-recover-full 2024-09-29T21:18:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/people-who-experience-side-effects-from-cranial-radiation-therapy-may-recover-full 2024-09-29T21:18:23+00:00 weekly 0.7 https://trial.medpath.com/news/and-high-risk-localized-prostate-cancer-results-from-the-getug-14-randomized-phase-iii-trial 2024-09-29T21:15:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/and-high-risk-localized-prostate-cancer-results-from-the-getug-14-randomized-phase-iii-trial 2024-09-29T21:15:57+00:00 weekly 0.7 https://trial.medpath.com/news/apac-clinical-services-market-set-to-reach-140-billion-by-2031-as-region-emerges-as-trial-powerhouse 2024-09-29T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apac-clinical-services-market-set-to-reach-140-billion-by-2031-as-region-emerges-as-trial-powerhouse 2024-09-29T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pbt-imrt-provide-similar-patient-reported-outcomes-for-prostate-cancer-at-5-years 2024-09-29T19:16:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pbt-imrt-provide-similar-patient-reported-outcomes-for-prostate-cancer-at-5-years 2024-09-29T19:16:45+00:00 weekly 0.7 https://trial.medpath.com/news/wall-street-swot-editas-medicine-stock-faces-challenges-in-competitive-gene-editing-market 2024-09-29T17:27:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wall-street-swot-editas-medicine-stock-faces-challenges-in-competitive-gene-editing-market 2024-09-29T17:27:39+00:00 weekly 0.7 https://trial.medpath.com/news/radiopharmaceutical-therapy-offers-promise-for-people-with-tough-to-treat-meningioma-brain-tumors 2024-09-29T17:03:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radiopharmaceutical-therapy-offers-promise-for-people-with-tough-to-treat-meningioma-brain-tumors 2024-09-29T17:03:47+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-submits-supplemental-new-drug-application-to-usfda-seeking-expanded-indication 2024-09-29T16:56:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-submits-supplemental-new-drug-application-to-usfda-seeking-expanded-indication 2024-09-29T16:56:59+00:00 weekly 0.7 https://trial.medpath.com/news/not-a-placebo-study-finds-meditation-offers-genuine-pain-relief-sciencealert 2024-09-29T16:26:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/not-a-placebo-study-finds-meditation-offers-genuine-pain-relief-sciencealert 2024-09-29T16:26:50+00:00 weekly 0.7 https://trial.medpath.com/news/first-interim-results-from-fine-real-a-prospective-non-interventional-phase-4-study 2024-09-29T15:15:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-interim-results-from-fine-real-a-prospective-non-interventional-phase-4-study 2024-09-29T15:15:34+00:00 weekly 0.7 https://trial.medpath.com/news/prior-local-therapy-does-not-impact-mcrpc-survival-with-arpi-treatment-urology-times 2024-09-29T14:40:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prior-local-therapy-does-not-impact-mcrpc-survival-with-arpi-treatment-urology-times 2024-09-29T14:40:52+00:00 weekly 0.7 https://trial.medpath.com/news/iaso-bio-presented-comparative-clinical-outcomes-on-the-optimal-lymphodepletion-prior 2024-09-29T14:26:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iaso-bio-presented-comparative-clinical-outcomes-on-the-optimal-lymphodepletion-prior 2024-09-29T14:26:47+00:00 weekly 0.7 https://trial.medpath.com/news/weekend-icymi-september-23-to-september-27-drug-topics 2024-09-29T14:24:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weekend-icymi-september-23-to-september-27-drug-topics 2024-09-29T14:24:42+00:00 weekly 0.7 https://trial.medpath.com/news/lumos-pharma-a-strong-buy-on-innovative-drug-prospects-and-solid-financials 2024-09-29T13:53:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lumos-pharma-a-strong-buy-on-innovative-drug-prospects-and-solid-financials 2024-09-29T13:53:59+00:00 weekly 0.7 https://trial.medpath.com/news/avicenna-ai-receives-fda-510-k-clearance-for-cervical-spine-fracture-ai-tool-healio 2024-09-29T13:51:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avicenna-ai-receives-fda-510-k-clearance-for-cervical-spine-fracture-ai-tool-healio 2024-09-29T13:51:13+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-highlights-new-data-from-helios-b-study-of-vutrisiran-for-the-treatment-of-quantisnow 2024-09-29T13:18:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alnylam-highlights-new-data-from-helios-b-study-of-vutrisiran-for-the-treatment-of-quantisnow 2024-09-29T13:18:13+00:00 weekly 0.7 https://trial.medpath.com/news/world-heart-day-2024-looking-back-at-cardiology-s-year-of-progress-in-cell-and-gene-therapy 2024-09-29T13:04:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/world-heart-day-2024-looking-back-at-cardiology-s-year-of-progress-in-cell-and-gene-therapy 2024-09-29T13:04:58+00:00 weekly 0.7 https://trial.medpath.com/news/study-protocol-for-early-tracking-of-childhood-health-determinants-etched 2024-09-29T12:24:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-protocol-for-early-tracking-of-childhood-health-determinants-etched 2024-09-29T12:24:15+00:00 weekly 0.7 https://trial.medpath.com/news/is-merck-stock-a-buy-the-globe-and-mail 2024-09-29T11:38:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/is-merck-stock-a-buy-the-globe-and-mail 2024-09-29T11:38:04+00:00 weekly 0.7 https://trial.medpath.com/news/858-therapeutics-drug-discovery-company-raises-50-million-series-b-pulse-2-0 2024-09-29T11:27:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/858-therapeutics-drug-discovery-company-raises-50-million-series-b-pulse-2-0 2024-09-29T11:27:01+00:00 weekly 0.7 https://trial.medpath.com/news/effects-of-tenofovir-alafenamide-fumarate-on-serum-lipid-profiles-in-patients-with-chronic-hepatitis-b 2024-09-29T10:31:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effects-of-tenofovir-alafenamide-fumarate-on-serum-lipid-profiles-in-patients-with-chronic-hepatitis-b 2024-09-29T10:31:37+00:00 weekly 0.7 https://trial.medpath.com/news/2020-acr-guidelines-challenge-traditional-gout-management-in-chronic-kidney-disease-patients 2024-09-29T10:00:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2020-acr-guidelines-challenge-traditional-gout-management-in-chronic-kidney-disease-patients 2024-09-29T10:00:15+00:00 weekly 0.7 https://trial.medpath.com/news/discussing-interim-findings-on-nemolizumab-for-atopic-dermatitis-with-diamant-thaci-md 2024-09-29T08:02:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/discussing-interim-findings-on-nemolizumab-for-atopic-dermatitis-with-diamant-thaci-md 2024-09-29T08:02:02+00:00 weekly 0.7 https://trial.medpath.com/news/shingrix-vaccine-shows-strong-protection-against-shingles-in-ibd-patients-mayo-clinic-study-finds 2024-09-29T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shingrix-vaccine-shows-strong-protection-against-shingles-in-ibd-patients-mayo-clinic-study-finds 2024-09-29T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/post-transplant-cyclophosphamide-breakthrough-expands-donor-pool-for-all-patients 2024-09-29T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/post-transplant-cyclophosphamide-breakthrough-expands-donor-pool-for-all-patients 2024-09-29T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/delavirdine-gains-approval-as-second-nnrti-for-anti-hiv-combination-regimens-pubmed 2024-09-29T05:45:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/delavirdine-gains-approval-as-second-nnrti-for-anti-hiv-combination-regimens-pubmed 2024-09-29T05:45:18+00:00 weekly 0.7 https://trial.medpath.com/news/targeting-primary-tumor-metastasized-lesions-linked-to-improved-5-year-omhspc-survival 2024-09-29T05:24:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/targeting-primary-tumor-metastasized-lesions-linked-to-improved-5-year-omhspc-survival 2024-09-29T05:24:16+00:00 weekly 0.7 https://trial.medpath.com/news/ga-68-psma-11-tracer-could-guide-scintix-radiation-therapy-for-metastasized-prostate-cancer 2024-09-29T04:43:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ga-68-psma-11-tracer-could-guide-scintix-radiation-therapy-for-metastasized-prostate-cancer 2024-09-29T04:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/abos-acumen-pharmaceuticals-inc-latest-stock-news-market-updates 2024-09-29T03:16:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abos-acumen-pharmaceuticals-inc-latest-stock-news-market-updates 2024-09-29T03:16:56+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-outcomes-of-patients-treated-with-ribociclib-in-combination-w-itt 2024-09-29T02:25:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-outcomes-of-patients-treated-with-ribociclib-in-combination-w-itt 2024-09-29T02:25:03+00:00 weekly 0.7 https://trial.medpath.com/news/virologic-suppression-rate-and-associated-factors-for-third-line-hiv-treatment-in-addis-ababa 2024-09-29T00:37:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/virologic-suppression-rate-and-associated-factors-for-third-line-hiv-treatment-in-addis-ababa 2024-09-29T00:37:58+00:00 weekly 0.7 https://trial.medpath.com/news/a-comparison-of-efficacy-of-erector-spinae-plane-block-versus-serratus-anterior-trials-journal 2024-09-28T23:37:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-comparison-of-efficacy-of-erector-spinae-plane-block-versus-serratus-anterior-trials-journal 2024-09-28T23:37:50+00:00 weekly 0.7 https://trial.medpath.com/news/a-synuclein-antibody-lu-af82422-shows-disease-modifying-potential-in-phase-2-amulet 2024-09-28T22:56:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-synuclein-antibody-lu-af82422-shows-disease-modifying-potential-in-phase-2-amulet 2024-09-28T22:56:04+00:00 weekly 0.7 https://trial.medpath.com/news/isatuximab-lenalidomide-demonstrates-strong-efficacy-tolerability-in-smoldering-multiple-myeloma 2024-09-28T22:10:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/isatuximab-lenalidomide-demonstrates-strong-efficacy-tolerability-in-smoldering-multiple-myeloma 2024-09-28T22:10:16+00:00 weekly 0.7 https://trial.medpath.com/news/stress-confirmed-as-trigger-for-psoriasis-relapse-mcknight-s-long-term-care-news 2024-09-28T21:38:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stress-confirmed-as-trigger-for-psoriasis-relapse-mcknight-s-long-term-care-news 2024-09-28T21:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/the-role-of-endovascular-therapy-for-stroke-patients-mcknight-s-long-term-care-news 2024-09-28T21:35:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-role-of-endovascular-therapy-for-stroke-patients-mcknight-s-long-term-care-news 2024-09-28T21:35:40+00:00 weekly 0.7 https://trial.medpath.com/news/study-protocol-for-a-cluster-randomized-controlled-community-effectiveness-trial-of-the 2024-09-28T21:31:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-protocol-for-a-cluster-randomized-controlled-community-effectiveness-trial-of-the 2024-09-28T21:31:34+00:00 weekly 0.7 https://trial.medpath.com/news/bgne-beigene-ltd-american-depositary-shares-latest-stock-news-market-updates 2024-09-28T21:18:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bgne-beigene-ltd-american-depositary-shares-latest-stock-news-market-updates 2024-09-28T21:18:45+00:00 weekly 0.7 https://trial.medpath.com/news/nurses-talk-aes-interstitial-lung-disease-before-treating-with-t-dxd 2024-09-28T21:00:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nurses-talk-aes-interstitial-lung-disease-before-treating-with-t-dxd 2024-09-28T21:00:12+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-nvision-s-3d-printed-peek-interbody-system-voxelmatters 2024-09-28T20:02:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-nvision-s-3d-printed-peek-interbody-system-voxelmatters 2024-09-28T20:02:32+00:00 weekly 0.7 https://trial.medpath.com/news/structural-basis-for-the-rescue-of-hyperexcitable-cells-by-the-amyotrophic-lateral-sclerosis 2024-09-28T19:58:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/structural-basis-for-the-rescue-of-hyperexcitable-cells-by-the-amyotrophic-lateral-sclerosis 2024-09-28T19:58:01+00:00 weekly 0.7 https://trial.medpath.com/news/omeicos-therapeutics-completes-enrollment-in-phase-2a-pmd-option-study-of-omt-28-in 2024-09-28T19:30:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/omeicos-therapeutics-completes-enrollment-in-phase-2a-pmd-option-study-of-omt-28-in 2024-09-28T19:30:22+00:00 weekly 0.7 https://trial.medpath.com/news/patient-reported-outcomes-similar-between-adalimumab-admb-reference-product-in 2024-09-28T17:07:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-reported-outcomes-similar-between-adalimumab-admb-reference-product-in 2024-09-28T17:07:06+00:00 weekly 0.7 https://trial.medpath.com/news/today-s-health-roundup-schizophrenia-breakthrough-and-bird-flu-vaccination-pressures 2024-09-28T16:58:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/today-s-health-roundup-schizophrenia-breakthrough-and-bird-flu-vaccination-pressures 2024-09-28T16:58:08+00:00 weekly 0.7 https://trial.medpath.com/news/neurological-aes-not-significantly-affiliated-with-talquetamab-treatment-cancer-network 2024-09-28T16:55:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurological-aes-not-significantly-affiliated-with-talquetamab-treatment-cancer-network 2024-09-28T16:55:50+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-breakthrough-treatment-for-anxious-dogs-with-no-side-effects 2024-09-28T15:16:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-breakthrough-treatment-for-anxious-dogs-with-no-side-effects 2024-09-28T15:16:37+00:00 weekly 0.7 https://trial.medpath.com/news/th17-cells-may-serve-as-biomarker-in-metastatic-melanoma-targeted-oncology 2024-09-28T15:02:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/th17-cells-may-serve-as-biomarker-in-metastatic-melanoma-targeted-oncology 2024-09-28T15:02:12+00:00 weekly 0.7 https://trial.medpath.com/news/intervention-to-reduce-sedentary-behavior-among-desk-workers-did-not-lower-blood-pressure 2024-09-28T14:38:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intervention-to-reduce-sedentary-behavior-among-desk-workers-did-not-lower-blood-pressure 2024-09-28T14:38:09+00:00 weekly 0.7 https://trial.medpath.com/news/new-intervention-to-protect-lungs-during-cardiac-surgery-feasible-safe-and-effective-study-finds 2024-09-28T14:31:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-intervention-to-protect-lungs-during-cardiac-surgery-feasible-safe-and-effective-study-finds 2024-09-28T14:31:32+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-estrogens-play-a-hidden-role-in-cancers-inhibiting-a-key-immune-cell 2024-09-28T14:26:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-finds-estrogens-play-a-hidden-role-in-cancers-inhibiting-a-key-immune-cell 2024-09-28T14:26:50+00:00 weekly 0.7 https://trial.medpath.com/news/zydus-gets-usfda-approval-to-produce-its-generic-prostate-cancer-drug-company-news 2024-09-28T14:17:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zydus-gets-usfda-approval-to-produce-its-generic-prostate-cancer-drug-company-news 2024-09-28T14:17:59+00:00 weekly 0.7 https://trial.medpath.com/news/naveris-to-showcase-advances-in-precision-surveillance-for-hpv-associated-morningstar 2024-09-28T13:42:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/naveris-to-showcase-advances-in-precision-surveillance-for-hpv-associated-morningstar 2024-09-28T13:42:45+00:00 weekly 0.7 https://trial.medpath.com/news/enliven-therapeutics-announces-positive-data-update-from-phase-1-clinical-trial-of-elvn 2024-09-28T13:40:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enliven-therapeutics-announces-positive-data-update-from-phase-1-clinical-trial-of-elvn 2024-09-28T13:40:42+00:00 weekly 0.7 https://trial.medpath.com/news/taiwan-s-anbogen-inks-deal-with-beigene-to-evaluate-combination-therapy-in-colorectal-cancer 2024-09-28T13:06:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/taiwan-s-anbogen-inks-deal-with-beigene-to-evaluate-combination-therapy-in-colorectal-cancer 2024-09-28T13:06:30+00:00 weekly 0.7 https://trial.medpath.com/news/dea-calls-to-increase-production-of-psychedelics-for-clinical-research-lucid-news 2024-09-28T12:28:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dea-calls-to-increase-production-of-psychedelics-for-clinical-research-lucid-news 2024-09-28T12:28:53+00:00 weekly 0.7 https://trial.medpath.com/news/new-clinical-data-demonstrate-excellent-lesion-durability-with-pulseselecttm-pulsed-field 2024-09-28T11:00:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-clinical-data-demonstrate-excellent-lesion-durability-with-pulseselecttm-pulsed-field 2024-09-28T11:00:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ge-healthcare-s-flurpiridaz-f-18-pet-radiotracer-for-cad 2024-09-28T10:10:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ge-healthcare-s-flurpiridaz-f-18-pet-radiotracer-for-cad 2024-09-28T10:10:43+00:00 weekly 0.7 https://trial.medpath.com/news/enanta-s-phase-ii-challenge-data-position-a-second-potential-rsv-therapy-scrip 2024-09-28T09:39:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enanta-s-phase-ii-challenge-data-position-a-second-potential-rsv-therapy-scrip 2024-09-28T09:39:36+00:00 weekly 0.7 https://trial.medpath.com/news/hypofractionated-radiation-therapy-improves-10-year-prostate-cancer-outcomes 2024-09-28T09:23:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hypofractionated-radiation-therapy-improves-10-year-prostate-cancer-outcomes 2024-09-28T09:23:36+00:00 weekly 0.7 https://trial.medpath.com/news/the-weekly-roundup-september-23-27-dermatology-times 2024-09-28T09:07:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-weekly-roundup-september-23-27-dermatology-times 2024-09-28T09:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/why-glp-1s-might-treat-a-plethora-of-conditions-becker-s-hospital-review 2024-09-28T08:34:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-glp-1s-might-treat-a-plethora-of-conditions-becker-s-hospital-review 2024-09-28T08:34:30+00:00 weekly 0.7 https://trial.medpath.com/news/carvykti-r-is-the-first-and-only-cell-therapy-to-significantly-extend-overall-survival-versus 2024-09-28T08:30:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/carvykti-r-is-the-first-and-only-cell-therapy-to-significantly-extend-overall-survival-versus 2024-09-28T08:30:34+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-cepheus-phase-3-study-shows-improvement-for-patients-with-multiple 2024-09-28T07:43:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-cepheus-phase-3-study-shows-improvement-for-patients-with-multiple 2024-09-28T07:43:50+00:00 weekly 0.7 https://trial.medpath.com/news/deuruxolitinib-shows-efficacy-in-hair-regrowth-patient-satisfaction-and-psychosocial 2024-09-28T07:22:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/deuruxolitinib-shows-efficacy-in-hair-regrowth-patient-satisfaction-and-psychosocial 2024-09-28T07:22:07+00:00 weekly 0.7 https://trial.medpath.com/news/novel-antibody-drug-conjugate-hdp-101-shows-promise-in-relapsed-multiple-myeloma 2024-09-28T07:01:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-antibody-drug-conjugate-hdp-101-shows-promise-in-relapsed-multiple-myeloma 2024-09-28T07:01:37+00:00 weekly 0.7 https://trial.medpath.com/news/radiation-therapy-the-immune-system-and-what-s-ahead-md-anderson-cancer-center 2024-09-28T07:00:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radiation-therapy-the-immune-system-and-what-s-ahead-md-anderson-cancer-center 2024-09-28T07:00:34+00:00 weekly 0.7 https://trial.medpath.com/news/glucocorticoid-receptor-targeting-with-relacorilant-may-improve-ovarian-cancer-outcomes 2024-09-28T06:34:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glucocorticoid-receptor-targeting-with-relacorilant-may-improve-ovarian-cancer-outcomes 2024-09-28T06:34:54+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-heightened-depression-risk-in-retinitis-pigmentosa-patients-particularly-among-young-adults 2024-09-28T06:21:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-heightened-depression-risk-in-retinitis-pigmentosa-patients-particularly-among-young-adults 2024-09-28T06:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/pop-biotechnologies-announces-phase-3-trial-interim-results-published-for-covid-19 2024-09-28T06:09:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pop-biotechnologies-announces-phase-3-trial-interim-results-published-for-covid-19 2024-09-28T06:09:54+00:00 weekly 0.7 https://trial.medpath.com/news/ultra-processed-foods-linked-to-17-higher-type-2-diabetes-risk-in-large-european-study 2024-09-28T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultra-processed-foods-linked-to-17-higher-type-2-diabetes-risk-in-large-european-study 2024-09-28T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/zelenectide-pevedotin-shows-early-promise-as-less-toxic-alternative-to-standard 2024-09-28T05:06:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zelenectide-pevedotin-shows-early-promise-as-less-toxic-alternative-to-standard 2024-09-28T05:06:12+00:00 weekly 0.7 https://trial.medpath.com/news/commonly-used-drug-could-transform-treatment-of-rare-muscle-disorder-medical-xpress 2024-09-28T05:04:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/commonly-used-drug-could-transform-treatment-of-rare-muscle-disorder-medical-xpress 2024-09-28T05:04:29+00:00 weekly 0.7 https://trial.medpath.com/news/olomorasib-combo-elicits-favorable-efficacy-in-nsclc-targeted-oncology 2024-09-28T05:01:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/olomorasib-combo-elicits-favorable-efficacy-in-nsclc-targeted-oncology 2024-09-28T05:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-submits-biologics-license-application-to-the-fda-for-telisotuzumab-vedotin-teliso 2024-09-28T04:17:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-submits-biologics-license-application-to-the-fda-for-telisotuzumab-vedotin-teliso 2024-09-28T04:17:25+00:00 weekly 0.7 https://trial.medpath.com/news/dietary-factors-show-protective-effects-against-iga-nephropathy-in-landmark-mendelian-study 2024-09-28T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dietary-factors-show-protective-effects-against-iga-nephropathy-in-landmark-mendelian-study 2024-09-28T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vitamin-d-for-the-management-of-chronic-obstructive-pulmonary-disease-pubmed 2024-09-28T02:43:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vitamin-d-for-the-management-of-chronic-obstructive-pulmonary-disease-pubmed 2024-09-28T02:43:51+00:00 weekly 0.7 https://trial.medpath.com/news/dr-victoria-kunene-on-personalised-colorectal-cancer-vaccines-for-prevention-and-therapy 2024-09-28T02:03:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-victoria-kunene-on-personalised-colorectal-cancer-vaccines-for-prevention-and-therapy 2024-09-28T02:03:51+00:00 weekly 0.7 https://trial.medpath.com/news/here-s-the-article-based-on-the-provided-information-by-investing-com 2024-09-28T01:48:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/here-s-the-article-based-on-the-provided-information-by-investing-com 2024-09-28T01:48:40+00:00 weekly 0.7 https://trial.medpath.com/news/effectiveness-of-the-dyadic-coping-intervention-of-social-participation-dcisp-for-stroke-survivors 2024-09-28T01:39:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effectiveness-of-the-dyadic-coping-intervention-of-social-participation-dcisp-for-stroke-survivors 2024-09-28T01:39:20+00:00 weekly 0.7 https://trial.medpath.com/news/wall-street-swot-aquestive-therapeutics-stock-poised-for-potential-breakthrough 2024-09-28T00:49:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wall-street-swot-aquestive-therapeutics-stock-poised-for-potential-breakthrough 2024-09-28T00:49:17+00:00 weekly 0.7 https://trial.medpath.com/news/cepheus-outcomes-support-daratumumab-plus-vrd-as-soc-in-multiple-myeloma 2024-09-28T00:06:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cepheus-outcomes-support-daratumumab-plus-vrd-as-soc-in-multiple-myeloma 2024-09-28T00:06:45+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-ind-clearance-for-minovia-s-phase-ib-mds-therapy-trial 2024-09-27T23:08:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-ind-clearance-for-minovia-s-phase-ib-mds-therapy-trial 2024-09-27T23:08:19+00:00 weekly 0.7 https://trial.medpath.com/news/dr-gluz-on-survival-outcomes-with-de-escalated-neoadjuvant-regimens-in-hr-her2 2024-09-27T22:53:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-gluz-on-survival-outcomes-with-de-escalated-neoadjuvant-regimens-in-hr-her2 2024-09-27T22:53:04+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-parkinson-s-drug-tavapadon-a-market-perform-rating-amidst-competitive 2024-09-27T22:24:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-s-parkinson-s-drug-tavapadon-a-market-perform-rating-amidst-competitive 2024-09-27T22:24:30+00:00 weekly 0.7 https://trial.medpath.com/news/late-breaking-data-at-eadv-of-esk-001-an-oral-tyk2-inhibitor-for-the-treatment-of-biospace 2024-09-27T22:02:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/late-breaking-data-at-eadv-of-esk-001-an-oral-tyk2-inhibitor-for-the-treatment-of-biospace 2024-09-27T22:02:52+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-expanded-indication-for-linear-health-sciences-orchid-safety-release-valve 2024-09-27T20:42:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-expanded-indication-for-linear-health-sciences-orchid-safety-release-valve 2024-09-27T20:42:13+00:00 weekly 0.7 https://trial.medpath.com/news/has-albrecht-been-undone-insights-holland-knight 2024-09-27T20:37:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/has-albrecht-been-undone-insights-holland-knight 2024-09-27T20:37:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-selpercatinib-for-ret-fusion-medullary-thyroid-cancer 2024-09-27T19:37:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-selpercatinib-for-ret-fusion-medullary-thyroid-cancer 2024-09-27T19:37:47+00:00 weekly 0.7 https://trial.medpath.com/news/boston-scientific-wins-farapulse-pfa-approval-in-japan-massdevice 2024-09-27T19:37:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boston-scientific-wins-farapulse-pfa-approval-in-japan-massdevice 2024-09-27T19:37:41+00:00 weekly 0.7 https://trial.medpath.com/news/cereno-scientific-announces-positive-topline-results-of-phase-iia-trial-with-lead-candidate 2024-09-27T18:42:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cereno-scientific-announces-positive-topline-results-of-phase-iia-trial-with-lead-candidate 2024-09-27T18:42:30+00:00 weekly 0.7 https://trial.medpath.com/news/neurona-therapeutics-announces-participation-in-upcoming-investor-conferences-in-october 2024-09-27T18:10:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurona-therapeutics-announces-participation-in-upcoming-investor-conferences-in-october 2024-09-27T18:10:49+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-to-present-phase-3-trial-design-for-sotagliflozin-globenewswire 2024-09-27T18:10:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexicon-to-present-phase-3-trial-design-for-sotagliflozin-globenewswire 2024-09-27T18:10:16+00:00 weekly 0.7 https://trial.medpath.com/news/grand-rounds-october-18-2024-rigorous-testing-of-behavior-change-interventions 2024-09-27T18:07:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grand-rounds-october-18-2024-rigorous-testing-of-behavior-change-interventions 2024-09-27T18:07:10+00:00 weekly 0.7 https://trial.medpath.com/news/staggering-breast-cancer-breakthrough-as-drug-trial-drastically-shrinks-tumours-by-65-uk 2024-09-27T18:00:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/staggering-breast-cancer-breakthrough-as-drug-trial-drastically-shrinks-tumours-by-65-uk 2024-09-27T18:00:30+00:00 weekly 0.7 https://trial.medpath.com/news/antibody-drug-conjugates-and-immune-checkpoint-inhibitors-in-cancer-treatment-nature 2024-09-27T17:28:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antibody-drug-conjugates-and-immune-checkpoint-inhibitors-in-cancer-treatment-nature 2024-09-27T17:28:28+00:00 weekly 0.7 https://trial.medpath.com/news/wall-street-swot-atyr-pharma-stock-rides-wave-of-clinical-progress-amid-risks 2024-09-27T17:14:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wall-street-swot-atyr-pharma-stock-rides-wave-of-clinical-progress-amid-risks 2024-09-27T17:14:56+00:00 weekly 0.7 https://trial.medpath.com/news/galectin-9-as-a-new-biomarker-of-acute-on-chronic-liver-failure-scientific-reports-nature 2024-09-27T16:25:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/galectin-9-as-a-new-biomarker-of-acute-on-chronic-liver-failure-scientific-reports-nature 2024-09-27T16:25:30+00:00 weekly 0.7 https://trial.medpath.com/news/biosimilars-generate-12-3-billion-in-healthcare-savings-for-2023-yet-market-challenges-persist 2024-09-27T16:00:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biosimilars-generate-12-3-billion-in-healthcare-savings-for-2023-yet-market-challenges-persist 2024-09-27T16:00:32+00:00 weekly 0.7 https://trial.medpath.com/news/pas-004-has-tolerable-safety-profile-and-preliminary-efficacy-in-mapk-driven-solid-tumors 2024-09-27T15:59:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pas-004-has-tolerable-safety-profile-and-preliminary-efficacy-in-mapk-driven-solid-tumors 2024-09-27T15:59:49+00:00 weekly 0.7 https://trial.medpath.com/news/in-first-type-1-diabetic-cured-by-allogeneic-stem-cell-transplant 2024-09-27T15:42:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in-first-type-1-diabetic-cured-by-allogeneic-stem-cell-transplant 2024-09-27T15:42:35+00:00 weekly 0.7 https://trial.medpath.com/news/nyu-langone-health-in-the-news-friday-september-27-2024 2024-09-27T15:26:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nyu-langone-health-in-the-news-friday-september-27-2024 2024-09-27T15:26:39+00:00 weekly 0.7 https://trial.medpath.com/news/lundbeck-presents-results-from-two-studies-in-multiple-system-atrophy-at-international 2024-09-27T15:20:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lundbeck-presents-results-from-two-studies-in-multiple-system-atrophy-at-international 2024-09-27T15:20:28+00:00 weekly 0.7 https://trial.medpath.com/news/rezolute-stock-holds-steady-with-buy-rating-from-hc-wainwright-investing-com 2024-09-27T15:13:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rezolute-stock-holds-steady-with-buy-rating-from-hc-wainwright-investing-com 2024-09-27T15:13:07+00:00 weekly 0.7 https://trial.medpath.com/news/key-considerations-for-digital-decentralised-clinical-trials-from-a-feasibility-study-assessing 2024-09-27T15:10:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/key-considerations-for-digital-decentralised-clinical-trials-from-a-feasibility-study-assessing 2024-09-27T15:10:30+00:00 weekly 0.7 https://trial.medpath.com/news/non-clinical-evaluation-of-pmil12-gene-therapy-for-approval-of-the-phase-i-clinical-study 2024-09-27T15:08:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/non-clinical-evaluation-of-pmil12-gene-therapy-for-approval-of-the-phase-i-clinical-study 2024-09-27T15:08:45+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-builds-case-for-talvey-fda-panel-questions-pd-1-drugs-for-certain-cancers 2024-09-27T14:58:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-builds-case-for-talvey-fda-panel-questions-pd-1-drugs-for-certain-cancers 2024-09-27T14:58:06+00:00 weekly 0.7 https://trial.medpath.com/news/the-data-are-clear-patients-regain-weight-after-stopping-glp-1-drugs-medpage-today 2024-09-27T14:46:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-data-are-clear-patients-regain-weight-after-stopping-glp-1-drugs-medpage-today 2024-09-27T14:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/practical-lessons-and-insights-from-seasoned-drug-hunters 2024-09-27T14:19:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/practical-lessons-and-insights-from-seasoned-drug-hunters 2024-09-27T14:19:46+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-shares-move-higher-on-fda-approval-of-schizophrenia-drug 2024-09-27T13:41:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-squibb-shares-move-higher-on-fda-approval-of-schizophrenia-drug 2024-09-27T13:41:01+00:00 weekly 0.7 https://trial.medpath.com/news/leo-pharma-files-for-approval-of-psoriasis-treatment-enstilar-in-china-medwatch 2024-09-27T13:33:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leo-pharma-files-for-approval-of-psoriasis-treatment-enstilar-in-china-medwatch 2024-09-27T13:33:49+00:00 weekly 0.7 https://trial.medpath.com/news/nccn-guidelines-update-evolving-treatment-landscape-for-graft-vs-host-disease-management 2024-09-27T13:00:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nccn-guidelines-update-evolving-treatment-landscape-for-graft-vs-host-disease-management 2024-09-27T13:00:54+00:00 weekly 0.7 https://trial.medpath.com/news/a-bayesian-multivariate-hierarchical-model-for-developing-a-treatment-benefit-index-using 2024-09-27T12:51:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-bayesian-multivariate-hierarchical-model-for-developing-a-treatment-benefit-index-using 2024-09-27T12:51:47+00:00 weekly 0.7 https://trial.medpath.com/news/septerna-announces-initiation-of-phase-1-clinical-trial-with-sep-786-a-novel-oral-small 2024-09-27T12:47:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/septerna-announces-initiation-of-phase-1-clinical-trial-with-sep-786-a-novel-oral-small 2024-09-27T12:47:32+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-s-bemdaneprocel-for-parkinson-s-disease-shows-positive-data-at-24-months 2024-09-27T12:33:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-s-bemdaneprocel-for-parkinson-s-disease-shows-positive-data-at-24-months 2024-09-27T12:33:29+00:00 weekly 0.7 https://trial.medpath.com/news/savara-announces-expanded-access-program-eap-for-molgramostim-inhalation-solution 2024-09-27T12:16:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/savara-announces-expanded-access-program-eap-for-molgramostim-inhalation-solution 2024-09-27T12:16:32+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-jefferies-lowers-price-target-marketscreener 2024-09-27T12:16:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-jefferies-lowers-price-target-marketscreener 2024-09-27T12:16:10+00:00 weekly 0.7 https://trial.medpath.com/news/cardurion-pharmaceuticals-selected-as-an-endpoints-11-most-promising-biotech-company 2024-09-27T12:12:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardurion-pharmaceuticals-selected-as-an-endpoints-11-most-promising-biotech-company 2024-09-27T12:12:38+00:00 weekly 0.7 https://trial.medpath.com/news/impact-biotech-announces-50-enrollment-in-phase-3-enlighted-clinical-trial-of 2024-09-27T12:08:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/impact-biotech-announces-50-enrollment-in-phase-3-enlighted-clinical-trial-of 2024-09-27T12:08:56+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-performance-analysis-of-gprc5d-bispecific-therapies-in-relapsed-multiple-myeloma 2024-09-27T11:50:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-performance-analysis-of-gprc5d-bispecific-therapies-in-relapsed-multiple-myeloma 2024-09-27T11:50:55+00:00 weekly 0.7 https://trial.medpath.com/news/mhra-approves-first-medicine-for-rare-immune-disease-apds-gov-uk 2024-09-27T11:37:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mhra-approves-first-medicine-for-rare-immune-disease-apds-gov-uk 2024-09-27T11:37:56+00:00 weekly 0.7 https://trial.medpath.com/news/reporting-and-communication-of-sample-size-calculations-in-adaptive-clinical-trials 2024-09-27T11:37:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reporting-and-communication-of-sample-size-calculations-in-adaptive-clinical-trials 2024-09-27T11:37:42+00:00 weekly 0.7 https://trial.medpath.com/news/stem-cells-reverse-woman-s-diabetes-a-world-first-healthleaders-media 2024-09-27T11:25:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stem-cells-reverse-woman-s-diabetes-a-world-first-healthleaders-media 2024-09-27T11:25:43+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-dupixent-approved-in-china-as-the-first-ever-biologic-medicine-for-patients 2024-09-27T11:14:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-dupixent-approved-in-china-as-the-first-ever-biologic-medicine-for-patients 2024-09-27T11:14:20+00:00 weekly 0.7 https://trial.medpath.com/news/poltreg-begins-car-treg-development-for-neuroinflammatory-disease 2024-09-27T11:05:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/poltreg-begins-car-treg-development-for-neuroinflammatory-disease 2024-09-27T11:05:48+00:00 weekly 0.7 https://trial.medpath.com/news/occlusive-retinal-vasculitis-associated-with-intravitreal-faricimab-injections 2024-09-27T10:41:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/occlusive-retinal-vasculitis-associated-with-intravitreal-faricimab-injections 2024-09-27T10:41:22+00:00 weekly 0.7 https://trial.medpath.com/news/alembic-pharma-secures-fda-approval-for-schizophrenia-treatment-stocks-in-red 2024-09-27T10:26:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alembic-pharma-secures-fda-approval-for-schizophrenia-treatment-stocks-in-red 2024-09-27T10:26:29+00:00 weekly 0.7 https://trial.medpath.com/news/ose-immunotherapeutics-announces-historic-h1-2024-results-and-provides-corporate-update 2024-09-27T09:45:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ose-immunotherapeutics-announces-historic-h1-2024-results-and-provides-corporate-update 2024-09-27T09:45:47+00:00 weekly 0.7 https://trial.medpath.com/news/a-multi-center-double-blind-placebo-controlled-randomized-parallel-group-non-inferiority 2024-09-27T09:39:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-multi-center-double-blind-placebo-controlled-randomized-parallel-group-non-inferiority 2024-09-27T09:39:56+00:00 weekly 0.7 https://trial.medpath.com/news/trial-of-pathogen-reduced-cryoprecipitate-vs-cryoprecipitated-ahf-to-lower-operative 2024-09-27T09:39:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trial-of-pathogen-reduced-cryoprecipitate-vs-cryoprecipitated-ahf-to-lower-operative 2024-09-27T09:39:56+00:00 weekly 0.7 https://trial.medpath.com/news/upping-dose-of-anti-opioid-drug-might-work-better-to-curb-addiction 2024-09-27T09:09:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/upping-dose-of-anti-opioid-drug-might-work-better-to-curb-addiction 2024-09-27T09:09:37+00:00 weekly 0.7 https://trial.medpath.com/news/viral-infections-emerge-as-critical-consideration-in-rheumatic-disease-management 2024-09-27T08:42:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viral-infections-emerge-as-critical-consideration-in-rheumatic-disease-management 2024-09-27T08:42:53+00:00 weekly 0.7 https://trial.medpath.com/news/dispute-over-duchenne-gene-therapy-highlights-thorny-access-issues-stat-news 2024-09-27T08:35:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dispute-over-duchenne-gene-therapy-highlights-thorny-access-issues-stat-news 2024-09-27T08:35:38+00:00 weekly 0.7 https://trial.medpath.com/news/urteste-expands-development-of-innovative-diagnostic-projects-biospace 2024-09-27T08:07:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/urteste-expands-development-of-innovative-diagnostic-projects-biospace 2024-09-27T08:07:46+00:00 weekly 0.7 https://trial.medpath.com/news/genprex-makes-moves-to-bring-its-gene-therapy-product-reqorsa-to-mesothelioma 2024-09-27T08:02:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genprex-makes-moves-to-bring-its-gene-therapy-product-reqorsa-to-mesothelioma 2024-09-27T08:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/formycon-and-fresenius-kabi-receive-european-commission-approval-for-fyb202-otulfi 2024-09-27T07:24:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/formycon-and-fresenius-kabi-receive-european-commission-approval-for-fyb202-otulfi 2024-09-27T07:24:52+00:00 weekly 0.7 https://trial.medpath.com/news/xbrane-provides-update-from-scientific-advice-with-us-fda-on-xdivanetm-opdivo 2024-09-27T07:04:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xbrane-provides-update-from-scientific-advice-with-us-fda-on-xdivanetm-opdivo 2024-09-27T07:04:17+00:00 weekly 0.7 https://trial.medpath.com/news/psma-targeted-radiopharmaceuticals-transform-advanced-prostate-cancer-treatment-landscape 2024-09-27T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psma-targeted-radiopharmaceuticals-transform-advanced-prostate-cancer-treatment-landscape 2024-09-27T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/shionogi-submits-new-drug-application-in-japan-for-zuranolone-as-a-treatment-for-major 2024-09-27T02:35:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shionogi-submits-new-drug-application-in-japan-for-zuranolone-as-a-treatment-for-major 2024-09-27T02:35:10+00:00 weekly 0.7 https://trial.medpath.com/news/pilot-study-of-il-1-antagonist-anakinra-for-treatment-of-endometriosis-dove-medical-press 2024-09-27T02:27:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pilot-study-of-il-1-antagonist-anakinra-for-treatment-of-endometriosis-dove-medical-press 2024-09-27T02:27:10+00:00 weekly 0.7 https://trial.medpath.com/news/travere-therapeutics-announces-voluntary-pause-of-enrollment-in-the-phase-3-harmony 2024-09-27T02:13:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/travere-therapeutics-announces-voluntary-pause-of-enrollment-in-the-phase-3-harmony 2024-09-27T02:13:08+00:00 weekly 0.7 https://trial.medpath.com/news/arpa-h-awards-27m-to-phare-bio-for-ai-powered-antibiotic-discovery-platform 2024-09-27T02:12:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arpa-h-awards-27m-to-phare-bio-for-ai-powered-antibiotic-discovery-platform 2024-09-27T02:12:39+00:00 weekly 0.7 https://trial.medpath.com/news/union-plans-phase-iii-trial-for-atopic-dermatitis-after-phase-iib-win-clinical-trials-arena 2024-09-27T01:25:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/union-plans-phase-iii-trial-for-atopic-dermatitis-after-phase-iib-win-clinical-trials-arena 2024-09-27T01:25:36+00:00 weekly 0.7 https://trial.medpath.com/news/biocon-partners-with-tabuk-to-launch-glp-1-therapies-across-middle-east-markets 2024-09-27T00:16:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biocon-partners-with-tabuk-to-launch-glp-1-therapies-across-middle-east-markets 2024-09-27T00:16:42+00:00 weekly 0.7 https://trial.medpath.com/news/surufatinib-plus-toripalimab-combined-with-etoposide-and-cisplatin-as-first-line-treatment-in-nature 2024-09-27T00:10:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/surufatinib-plus-toripalimab-combined-with-etoposide-and-cisplatin-as-first-line-treatment-in-nature 2024-09-27T00:10:29+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-submits-biologics-license-application-to-the-fda-for-telisotuzumab-vedotin-teliso-v-in-previously-treated-non-small-cell-lung-cancer 2024-09-27T00:09:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-submits-biologics-license-application-to-the-fda-for-telisotuzumab-vedotin-teliso-v-in-previously-treated-non-small-cell-lung-cancer 2024-09-27T00:09:06+00:00 weekly 0.7 https://trial.medpath.com/news/canadian-real-world-study-finds-no-increased-infection-risk-with-tnf-inhibitor-biosimilars 2024-09-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/canadian-real-world-study-finds-no-increased-infection-risk-with-tnf-inhibitor-biosimilars 2024-09-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-published-data-show-reproducibility-and-utility-of-perspectum-s-mri-in-patients-with 2024-09-26T23:33:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-published-data-show-reproducibility-and-utility-of-perspectum-s-mri-in-patients-with 2024-09-26T23:33:17+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-sciences-shares-fall-after-sec-charges-for-misleading-alzheimer-s-drug-trial-claims 2024-09-26T23:08:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cassava-sciences-shares-fall-after-sec-charges-for-misleading-alzheimer-s-drug-trial-claims 2024-09-26T23:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-and-2seventy-bio-halt-karmma-9-trial-in-patients-with-newly 2024-09-26T21:11:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-squibb-and-2seventy-bio-halt-karmma-9-trial-in-patients-with-newly 2024-09-26T21:11:45+00:00 weekly 0.7 https://trial.medpath.com/news/establishment-labs-receives-u-s-fda-approval-for-motiva-implants-yahoo-finance 2024-09-26T21:09:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/establishment-labs-receives-u-s-fda-approval-for-motiva-implants-yahoo-finance 2024-09-26T21:09:43+00:00 weekly 0.7 https://trial.medpath.com/news/intrapatient-intermetastatic-heterogeneity-determined-by-triple-tracer-pet-imaging-in 2024-09-26T20:47:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intrapatient-intermetastatic-heterogeneity-determined-by-triple-tracer-pet-imaging-in 2024-09-26T20:47:15+00:00 weekly 0.7 https://trial.medpath.com/news/vivani-can-begin-first-in-human-glp-1-implant-trial-in-australia-drug-delivery-business 2024-09-26T19:59:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vivani-can-begin-first-in-human-glp-1-implant-trial-in-australia-drug-delivery-business 2024-09-26T19:59:55+00:00 weekly 0.7 https://trial.medpath.com/news/belantamab-combo-shows-promising-outcomes-in-transplant-eligible-ndmm 2024-09-26T19:49:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/belantamab-combo-shows-promising-outcomes-in-transplant-eligible-ndmm 2024-09-26T19:49:41+00:00 weekly 0.7 https://trial.medpath.com/news/orion-s-collaboration-partner-bayer-submits-application-to-u-s-fda-for-third-indication-of 2024-09-26T19:33:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/orion-s-collaboration-partner-bayer-submits-application-to-u-s-fda-for-third-indication-of 2024-09-26T19:33:57+00:00 weekly 0.7 https://trial.medpath.com/news/cyclacel-pharmaceuticals-announces-completion-of-enrollment-in-the-biomarker-enriched 2024-09-26T19:33:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cyclacel-pharmaceuticals-announces-completion-of-enrollment-in-the-biomarker-enriched 2024-09-26T19:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/enanta-pharmaceuticals-announces-positive-topline-results-for-edp-323-in-a-phase-biospace 2024-09-26T19:33:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enanta-pharmaceuticals-announces-positive-topline-results-for-edp-323-in-a-phase-biospace 2024-09-26T19:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/israeli-device-is-new-drug-free-solution-for-men-coping-with-ed-nocamels 2024-09-26T19:28:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/israeli-device-is-new-drug-free-solution-for-men-coping-with-ed-nocamels 2024-09-26T19:28:11+00:00 weekly 0.7 https://trial.medpath.com/news/placebos-linked-to-potential-harms-in-ibd-clinical-trials-medpage-today 2024-09-26T19:00:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/placebos-linked-to-potential-harms-in-ibd-clinical-trials-medpage-today 2024-09-26T19:00:50+00:00 weekly 0.7 https://trial.medpath.com/news/genentech-s-gazyva-hits-primary-endpoint-in-late-stage-kidney-disease-trial 2024-09-26T18:42:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genentech-s-gazyva-hits-primary-endpoint-in-late-stage-kidney-disease-trial 2024-09-26T18:42:57+00:00 weekly 0.7 https://trial.medpath.com/news/fda-lifts-clinical-hold-on-bmf-219-in-type-2-and-type-1-diabetes-trials-morningstar 2024-09-26T18:35:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-lifts-clinical-hold-on-bmf-219-in-type-2-and-type-1-diabetes-trials-morningstar 2024-09-26T18:35:33+00:00 weekly 0.7 https://trial.medpath.com/news/based-on-hope-and-love-ub-celebrates-opening-of-foxg1-research-center-ubnow 2024-09-26T18:02:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/based-on-hope-and-love-ub-celebrates-opening-of-foxg1-research-center-ubnow 2024-09-26T18:02:51+00:00 weekly 0.7 https://trial.medpath.com/news/thrombolytic-science-receives-fda-investigational-new-drug-clearance 2024-09-26T18:02:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/thrombolytic-science-receives-fda-investigational-new-drug-clearance 2024-09-26T18:02:08+00:00 weekly 0.7 https://trial.medpath.com/news/journalists-question-safety-and-effectiveness-of-new-alzheimer-s-drug 2024-09-26T17:49:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/journalists-question-safety-and-effectiveness-of-new-alzheimer-s-drug 2024-09-26T17:49:27+00:00 weekly 0.7 https://trial.medpath.com/news/patient-friendly-news-you-can-use-september-creakyjoints 2024-09-26T17:35:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-friendly-news-you-can-use-september-creakyjoints 2024-09-26T17:35:34+00:00 weekly 0.7 https://trial.medpath.com/news/eye-on-pharma-ec-approved-ustekinumab-zymfentra-expansion-biosimilar-policy-briefing 2024-09-26T17:26:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eye-on-pharma-ec-approved-ustekinumab-zymfentra-expansion-biosimilar-policy-briefing 2024-09-26T17:26:39+00:00 weekly 0.7 https://trial.medpath.com/news/eyenovia-announces-launch-and-commercial-availability-of-clobetasol-propionate-quantisnow 2024-09-26T17:21:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eyenovia-announces-launch-and-commercial-availability-of-clobetasol-propionate-quantisnow 2024-09-26T17:21:56+00:00 weekly 0.7 https://trial.medpath.com/news/polarcool-takes-an-important-step-towards-launching-in-the-us-cision-news 2024-09-26T16:50:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/polarcool-takes-an-important-step-towards-launching-in-the-us-cision-news 2024-09-26T16:50:56+00:00 weekly 0.7 https://trial.medpath.com/news/biomedical-research-improvements-needed-to-the-quality-of-information-about-dod-and 2024-09-26T16:49:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomedical-research-improvements-needed-to-the-quality-of-information-about-dod-and 2024-09-26T16:49:04+00:00 weekly 0.7 https://trial.medpath.com/news/her2-and-lung-cancer-new-test-holds-great-promise-to-help-far-more-patients 2024-09-26T16:36:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/her2-and-lung-cancer-new-test-holds-great-promise-to-help-far-more-patients 2024-09-26T16:36:53+00:00 weekly 0.7 https://trial.medpath.com/news/intrathecal-pain-pump-improves-pancreatic-cancer-patient-s-life 2024-09-26T16:36:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intrathecal-pain-pump-improves-pancreatic-cancer-patient-s-life 2024-09-26T16:36:16+00:00 weekly 0.7 https://trial.medpath.com/news/new-self-swab-hpv-test-is-an-alternative-to-pap-smears-here-s-how-it-works-live-science 2024-09-26T16:30:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-self-swab-hpv-test-is-an-alternative-to-pap-smears-here-s-how-it-works-live-science 2024-09-26T16:30:06+00:00 weekly 0.7 https://trial.medpath.com/news/axonics-wins-regulatory-nod-in-australia-for-latest-sacral-neuromod-system-massdevice 2024-09-26T16:01:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/axonics-wins-regulatory-nod-in-australia-for-latest-sacral-neuromod-system-massdevice 2024-09-26T16:01:47+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-blamed-after-children-offered-ps1500-to-take-part-in-covid-19-trial 2024-09-26T15:58:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-blamed-after-children-offered-ps1500-to-take-part-in-covid-19-trial 2024-09-26T15:58:40+00:00 weekly 0.7 https://trial.medpath.com/news/nih-plots-path-forward-for-clinical-trials-of-long-covid-treatments-c-en 2024-09-26T15:50:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-plots-path-forward-for-clinical-trials-of-long-covid-treatments-c-en 2024-09-26T15:50:34+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-announces-positive-topline-results-from-phase-3-tempo-1-trial-evaluating 2024-09-26T15:38:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-announces-positive-topline-results-from-phase-3-tempo-1-trial-evaluating 2024-09-26T15:38:07+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-withdraws-scd-drug-oxbryta-after-ema-discloses-16-deaths-in-trials 2024-09-26T15:37:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-withdraws-scd-drug-oxbryta-after-ema-discloses-16-deaths-in-trials 2024-09-26T15:37:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-proposes-reclassifying-hepatitis-b-assays-medtech-dive 2024-09-26T15:20:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-proposes-reclassifying-hepatitis-b-assays-medtech-dive 2024-09-26T15:20:15+00:00 weekly 0.7 https://trial.medpath.com/news/press-releases-wednesday-sep-25-2024-genentech 2024-09-26T15:11:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-releases-wednesday-sep-25-2024-genentech 2024-09-26T15:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/immunai-astrazeneca-collaborate-to-optimize-cancer-clinical-trials-the-jerusalem-post 2024-09-26T15:10:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunai-astrazeneca-collaborate-to-optimize-cancer-clinical-trials-the-jerusalem-post 2024-09-26T15:10:45+00:00 weekly 0.7 https://trial.medpath.com/news/kidney-cancer-questions-answered-from-protein-intake-to-clinical-trials-cure-today 2024-09-26T15:05:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kidney-cancer-questions-answered-from-protein-intake-to-clinical-trials-cure-today 2024-09-26T15:05:31+00:00 weekly 0.7 https://trial.medpath.com/news/breast-cancer-drugs-fda-approval-development-time-efficacy-clinical-benefits-innovation 2024-09-26T14:43:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breast-cancer-drugs-fda-approval-development-time-efficacy-clinical-benefits-innovation 2024-09-26T14:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-lunar-trial-dr-rolfo-discusses-new-analysis-at-iaslc-2024-world-conference 2024-09-26T14:43:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-lunar-trial-dr-rolfo-discusses-new-analysis-at-iaslc-2024-world-conference 2024-09-26T14:43:12+00:00 weekly 0.7 https://trial.medpath.com/news/govt-drafts-sop-to-regulate-clinical-research-organizations-mint 2024-09-26T14:40:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/govt-drafts-sop-to-regulate-clinical-research-organizations-mint 2024-09-26T14:40:16+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-breakthrough-as-wonder-drug-approved-but-might-not-be-available-in-the-uk 2024-09-26T14:14:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-breakthrough-as-wonder-drug-approved-but-might-not-be-available-in-the-uk 2024-09-26T14:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/rx-road-map-glofitamab-gxbm-columvi-oncology-nursing-news 2024-09-26T14:10:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rx-road-map-glofitamab-gxbm-columvi-oncology-nursing-news 2024-09-26T14:10:04+00:00 weekly 0.7 https://trial.medpath.com/news/eadv-2024-wegovy-shows-promise-in-treating-common-chronic-skin-condition 2024-09-26T13:42:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eadv-2024-wegovy-shows-promise-in-treating-common-chronic-skin-condition 2024-09-26T13:42:45+00:00 weekly 0.7 https://trial.medpath.com/news/a-first-in-human-study-of-cinrebafusp-alfa-a-her2-4-1bb-bispecific-molecule-in-patients 2024-09-26T13:28:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-first-in-human-study-of-cinrebafusp-alfa-a-her2-4-1bb-bispecific-molecule-in-patients 2024-09-26T13:28:32+00:00 weekly 0.7 https://trial.medpath.com/news/acasti-pharma-shares-maintain-buy-rating-from-hc-wainwright-investing-com 2024-09-26T13:26:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acasti-pharma-shares-maintain-buy-rating-from-hc-wainwright-investing-com 2024-09-26T13:26:39+00:00 weekly 0.7 https://trial.medpath.com/news/longeveron-to-attend-alliance-for-regenerative-medicine-s-cell-gene-meeting-on-the-mesa 2024-09-26T13:11:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/longeveron-to-attend-alliance-for-regenerative-medicine-s-cell-gene-meeting-on-the-mesa 2024-09-26T13:11:27+00:00 weekly 0.7 https://trial.medpath.com/news/metabolic-reprogramming-of-t-cells-may-enhance-checkpoint-inhibitor-therapy-newsroom 2024-09-26T13:10:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/metabolic-reprogramming-of-t-cells-may-enhance-checkpoint-inhibitor-therapy-newsroom 2024-09-26T13:10:23+00:00 weekly 0.7 https://trial.medpath.com/news/mural-oncology-s-first-virtual-investor-day-to-highlight-late-stage-clinical-progress 2024-09-26T12:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mural-oncology-s-first-virtual-investor-day-to-highlight-late-stage-clinical-progress 2024-09-26T12:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/cervomed-to-deliver-late-breaking-oral-presentations-at-the-17th-clinical-trials-on 2024-09-26T12:32:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cervomed-to-deliver-late-breaking-oral-presentations-at-the-17th-clinical-trials-on 2024-09-26T12:32:21+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-ptc518-huntington-s-disease-program-stock-titan 2024-09-26T12:17:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-ptc518-huntington-s-disease-program-stock-titan 2024-09-26T12:17:27+00:00 weekly 0.7 https://trial.medpath.com/news/projenx-and-unlearn-announce-partnership-to-augment-als-clinical-trial-pro-101-with 2024-09-26T12:00:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/projenx-and-unlearn-announce-partnership-to-augment-als-clinical-trial-pro-101-with 2024-09-26T12:00:29+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-highlights-first-oral-presentation-of-phase-3-clinical-data-of-the-vanza-triple-and 2024-09-26T11:34:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vertex-highlights-first-oral-presentation-of-phase-3-clinical-data-of-the-vanza-triple-and 2024-09-26T11:34:32+00:00 weekly 0.7 https://trial.medpath.com/news/dong-a-st-s-ecg-monitoring-platform-hicardi-h100-receives-u-s-fda-approval 2024-09-26T11:13:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dong-a-st-s-ecg-monitoring-platform-hicardi-h100-receives-u-s-fda-approval 2024-09-26T11:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/ani-pharmaceuticals-announces-fda-approval-launch-of-ketoconazole-shampoo-2 2024-09-26T10:57:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ani-pharmaceuticals-announces-fda-approval-launch-of-ketoconazole-shampoo-2 2024-09-26T10:57:11+00:00 weekly 0.7 https://trial.medpath.com/news/hamlet-biopharma-reports-positive-results-from-phase-ii-study-in-acute-cystitis 2024-09-26T10:38:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hamlet-biopharma-reports-positive-results-from-phase-ii-study-in-acute-cystitis 2024-09-26T10:38:10+00:00 weekly 0.7 https://trial.medpath.com/news/novel-monoclonal-antibody-shows-promise-in-ulcerative-colitis-medpage-today 2024-09-26T10:35:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-monoclonal-antibody-shows-promise-in-ulcerative-colitis-medpage-today 2024-09-26T10:35:13+00:00 weekly 0.7 https://trial.medpath.com/news/during-ny-climate-week-alex-zhavoronkov-phd-eurekalert 2024-09-26T10:21:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/during-ny-climate-week-alex-zhavoronkov-phd-eurekalert 2024-09-26T10:21:53+00:00 weekly 0.7 https://trial.medpath.com/news/innovent-announces-nmpa-acceptance-of-nda-for-picankibart-anti-il-23p19-antibody-for 2024-09-26T10:15:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovent-announces-nmpa-acceptance-of-nda-for-picankibart-anti-il-23p19-antibody-for 2024-09-26T10:15:54+00:00 weekly 0.7 https://trial.medpath.com/news/finance-to-pharma-q-a-with-renee-aguiar-lucander-pharmaceutical-executive 2024-09-26T10:07:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/finance-to-pharma-q-a-with-renee-aguiar-lucander-pharmaceutical-executive 2024-09-26T10:07:28+00:00 weekly 0.7 https://trial.medpath.com/news/inbiome-receives-fda-breakthrough-device-designation-for-revolutionary-molecular 2024-09-26T09:46:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inbiome-receives-fda-breakthrough-device-designation-for-revolutionary-molecular 2024-09-26T09:46:17+00:00 weekly 0.7 https://trial.medpath.com/news/amgn-a-stock-on-the-move-that-s-blessed-with-a-promising-drug-pipeline-moneyshow 2024-09-26T09:37:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgn-a-stock-on-the-move-that-s-blessed-with-a-promising-drug-pipeline-moneyshow 2024-09-26T09:37:42+00:00 weekly 0.7 https://trial.medpath.com/news/trial-confirms-life-changing-impact-of-gene-therapy-for-hemophilia-b 2024-09-26T09:37:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trial-confirms-life-changing-impact-of-gene-therapy-for-hemophilia-b 2024-09-26T09:37:31+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-therapy-designation-btd-for-biocity-s-sc0062-a-selective-endothelin-type 2024-09-26T09:20:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-therapy-designation-btd-for-biocity-s-sc0062-a-selective-endothelin-type 2024-09-26T09:20:10+00:00 weekly 0.7 https://trial.medpath.com/news/1st-pediatric-insomnia-drug-launched-in-korea-pharma-article-kbr 2024-09-26T08:44:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/1st-pediatric-insomnia-drug-launched-in-korea-pharma-article-kbr 2024-09-26T08:44:51+00:00 weekly 0.7 https://trial.medpath.com/news/cuh-plays-key-role-in-international-cancer-studies-cambridge-university-hospitals 2024-09-26T08:35:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cuh-plays-key-role-in-international-cancer-studies-cambridge-university-hospitals 2024-09-26T08:35:54+00:00 weekly 0.7 https://trial.medpath.com/news/obesity-drug-developer-bioage-raises-198m-in-ipo-pharmaphorum 2024-09-26T08:04:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/obesity-drug-developer-bioage-raises-198m-in-ipo-pharmaphorum 2024-09-26T08:04:35+00:00 weekly 0.7 https://trial.medpath.com/news/arthex-biotech-announces-participation-in-8th-annual-chardan-genetic-medicines-conference 2024-09-26T08:04:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arthex-biotech-announces-participation-in-8th-annual-chardan-genetic-medicines-conference 2024-09-26T08:04:24+00:00 weekly 0.7 https://trial.medpath.com/news/cabaletta-bio-to-present-new-and-updated-clinical-data-on-caba-201-in-oral-and-poster 2024-09-26T07:57:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cabaletta-bio-to-present-new-and-updated-clinical-data-on-caba-201-in-oral-and-poster 2024-09-26T07:57:05+00:00 weekly 0.7 https://trial.medpath.com/news/renovorx-increases-production-of-fda-cleared-renovocath-r-delivery-system-in-biospace 2024-09-26T07:45:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/renovorx-increases-production-of-fda-cleared-renovocath-r-delivery-system-in-biospace 2024-09-26T07:45:02+00:00 weekly 0.7 https://trial.medpath.com/news/who-issues-new-guidance-to-enhance-clinical-trials-worldwide-news-medical 2024-09-26T07:33:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/who-issues-new-guidance-to-enhance-clinical-trials-worldwide-news-medical 2024-09-26T07:33:08+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-pulls-sickle-cell-treatment-over-deadly-complication-risks-geneonline-news 2024-09-26T07:10:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-pulls-sickle-cell-treatment-over-deadly-complication-risks-geneonline-news 2024-09-26T07:10:39+00:00 weekly 0.7 https://trial.medpath.com/news/synairgen-making-substantial-progress-towards-phase-ii-trial-aim-sng-otc-syggf 2024-09-26T07:08:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/synairgen-making-substantial-progress-towards-phase-ii-trial-aim-sng-otc-syggf 2024-09-26T07:08:33+00:00 weekly 0.7 https://trial.medpath.com/news/elixirgen-therapeutics-receives-rare-pediatric-disease-designation-for-exg-34217-in-biospace 2024-09-26T07:03:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elixirgen-therapeutics-receives-rare-pediatric-disease-designation-for-exg-34217-in-biospace 2024-09-26T07:03:28+00:00 weekly 0.7 https://trial.medpath.com/news/cidara-therapeutics-announces-two-presentations-on-innovative-drug-fc-conjugate 2024-09-26T06:16:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cidara-therapeutics-announces-two-presentations-on-innovative-drug-fc-conjugate 2024-09-26T06:16:56+00:00 weekly 0.7 https://trial.medpath.com/news/palisade-bio-provides-update-on-progress-toward-launch-of-phase-1-human-clinical-biospace 2024-09-26T06:16:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/palisade-bio-provides-update-on-progress-toward-launch-of-phase-1-human-clinical-biospace 2024-09-26T06:16:55+00:00 weekly 0.7 https://trial.medpath.com/news/personalized-medicine-and-genetic-markers-drive-major-advances-in-pediatric-cancer-treatment 2024-09-26T06:00:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/personalized-medicine-and-genetic-markers-drive-major-advances-in-pediatric-cancer-treatment 2024-09-26T06:00:53+00:00 weekly 0.7 https://trial.medpath.com/news/cellbion-eyes-global-expansion-in-radiopharmaceuticals-after-kosdaq-ipo-kbr 2024-09-26T05:47:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cellbion-eyes-global-expansion-in-radiopharmaceuticals-after-kosdaq-ipo-kbr 2024-09-26T05:47:50+00:00 weekly 0.7 https://trial.medpath.com/news/mirai-bio-launches-50m-ai-platform-to-accelerate-genetic-medicine-development 2024-09-26T05:21:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mirai-bio-launches-50m-ai-platform-to-accelerate-genetic-medicine-development 2024-09-26T05:21:30+00:00 weekly 0.7 https://trial.medpath.com/news/a-two-pronged-attack-on-ovarian-cancer-hmri 2024-09-26T05:02:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-two-pronged-attack-on-ovarian-cancer-hmri 2024-09-26T05:02:01+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-treatment-for-recurrent-pregnancy-loss-mirage-news 2024-09-26T04:11:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-treatment-for-recurrent-pregnancy-loss-mirage-news 2024-09-26T04:11:13+00:00 weekly 0.7 https://trial.medpath.com/news/post-stroke-fever-prevention-still-lacking-in-clinical-benefit-medpage-today 2024-09-26T03:42:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/post-stroke-fever-prevention-still-lacking-in-clinical-benefit-medpage-today 2024-09-26T03:42:31+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-agonists-poised-to-impact-breast-cancer-care-targeted-oncology 2024-09-26T03:04:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glp-1-agonists-poised-to-impact-breast-cancer-care-targeted-oncology 2024-09-26T03:04:47+00:00 weekly 0.7 https://trial.medpath.com/news/uk-labour-government-s-nhs-reform-ai-and-technology-at-forefront-of-10-year-healthcare-transformation-plan 2024-09-26T02:30:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-labour-government-s-nhs-reform-ai-and-technology-at-forefront-of-10-year-healthcare-transformation-plan 2024-09-26T02:30:03+00:00 weekly 0.7 https://trial.medpath.com/news/daehwa-pharm-s-liporaxel-wins-chinese-approval-to-treat-gastric-cancer-pharma-article-kbr 2024-09-26T02:29:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/daehwa-pharm-s-liporaxel-wins-chinese-approval-to-treat-gastric-cancer-pharma-article-kbr 2024-09-26T02:29:38+00:00 weekly 0.7 https://trial.medpath.com/news/synergy-spine-solutions-announces-completion-of-patient-enrollment-in-the-synergy-disc 2024-09-26T02:06:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/synergy-spine-solutions-announces-completion-of-patient-enrollment-in-the-synergy-disc 2024-09-26T02:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/medidata-streamlines-clinical-trial-compensation-with-new-patient-payments-platform 2024-09-26T00:38:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medidata-streamlines-clinical-trial-compensation-with-new-patient-payments-platform 2024-09-26T00:38:03+00:00 weekly 0.7 https://trial.medpath.com/news/entera-bio-and-opko-health-provide-update-on-pk-pd-results-of-oral-oxyntomodulin-glp 2024-09-26T00:30:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/entera-bio-and-opko-health-provide-update-on-pk-pd-results-of-oral-oxyntomodulin-glp 2024-09-26T00:30:02+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-sees-promise-in-cd73-apexonco-clinical-trials-news-and-analysis 2024-09-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-sees-promise-in-cd73-apexonco-clinical-trials-news-and-analysis 2024-09-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/discovery-of-tyra-300-first-oral-selective-fgfr3 2024-09-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/discovery-of-tyra-300-first-oral-selective-fgfr3 2024-09-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/anixa-announces-plans-to-launch-phase-ii-breast-cancer-vaccine-trial 2024-09-25T23:21:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anixa-announces-plans-to-launch-phase-ii-breast-cancer-vaccine-trial 2024-09-25T23:21:10+00:00 weekly 0.7 https://trial.medpath.com/news/yourchoice-doses-participants-in-trial-of-birth-control-pill-for-men 2024-09-25T23:21:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/yourchoice-doses-participants-in-trial-of-birth-control-pill-for-men 2024-09-25T23:21:06+00:00 weekly 0.7 https://trial.medpath.com/news/biomarker-data-from-oncology-trial-for-adicet-bio-s-game-delta-t-cell-therapy-adi-001 2024-09-25T23:08:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomarker-data-from-oncology-trial-for-adicet-bio-s-game-delta-t-cell-therapy-adi-001 2024-09-25T23:08:35+00:00 weekly 0.7 https://trial.medpath.com/news/new-analysis-demonstrates-the-efficacy-of-rinvoq-r-upadacitinib-in-atopic-dermatitis 2024-09-25T23:04:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-analysis-demonstrates-the-efficacy-of-rinvoq-r-upadacitinib-in-atopic-dermatitis 2024-09-25T23:04:45+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-drug-faces-scrutiny-over-safety-efficacy-concerns-neuroscience-news 2024-09-25T22:56:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-drug-faces-scrutiny-over-safety-efficacy-concerns-neuroscience-news 2024-09-25T22:56:09+00:00 weekly 0.7 https://trial.medpath.com/news/sam-neill-credits-breakthrough-cancer-treatment-for-saving-his-life-easterneye 2024-09-25T22:41:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sam-neill-credits-breakthrough-cancer-treatment-for-saving-his-life-easterneye 2024-09-25T22:41:05+00:00 weekly 0.7 https://trial.medpath.com/news/uthealth-houston-s-minimally-invasive-treatment-newswise 2024-09-25T22:28:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uthealth-houston-s-minimally-invasive-treatment-newswise 2024-09-25T22:28:29+00:00 weekly 0.7 https://trial.medpath.com/news/struggling-2seventy-scraps-a-key-cancer-study-biopharma-dive 2024-09-25T21:52:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/struggling-2seventy-scraps-a-key-cancer-study-biopharma-dive 2024-09-25T21:52:25+00:00 weekly 0.7 https://trial.medpath.com/news/novel-antiviral-appears-effective-for-severe-rsv-in-infants-toddlers-medpage-today 2024-09-25T21:42:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-antiviral-appears-effective-for-severe-rsv-in-infants-toddlers-medpage-today 2024-09-25T21:42:57+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approved-topical-ruxolitinib-and-the-evolving-treatment-paradigm-dermatology-times 2024-09-25T21:31:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approved-topical-ruxolitinib-and-the-evolving-treatment-paradigm-dermatology-times 2024-09-25T21:31:52+00:00 weekly 0.7 https://trial.medpath.com/news/type-2-diabetes-study-the-reporter-uab 2024-09-25T21:08:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/type-2-diabetes-study-the-reporter-uab 2024-09-25T21:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/pola-r-chp-or-r-choep-for-first-line-therapy-of-younger-patients-with-high-risk-diffuse-large 2024-09-25T20:37:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pola-r-chp-or-r-choep-for-first-line-therapy-of-younger-patients-with-high-risk-diffuse-large 2024-09-25T20:37:58+00:00 weekly 0.7 https://trial.medpath.com/news/peaky-blinders-star-says-he-would-be-dead-if-not-for-experimental-drug 2024-09-25T20:36:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/peaky-blinders-star-says-he-would-be-dead-if-not-for-experimental-drug 2024-09-25T20:36:18+00:00 weekly 0.7 https://trial.medpath.com/news/unc-fast-tracks-personalized-treatment-for-twins-with-ultra-rare-genetic-disorder 2024-09-25T20:31:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unc-fast-tracks-personalized-treatment-for-twins-with-ultra-rare-genetic-disorder 2024-09-25T20:31:59+00:00 weekly 0.7 https://trial.medpath.com/news/experts-share-intriguing-early-phase-sarcoma-studies-from-the-2024-esmo-congress 2024-09-25T20:23:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-share-intriguing-early-phase-sarcoma-studies-from-the-2024-esmo-congress 2024-09-25T20:23:59+00:00 weekly 0.7 https://trial.medpath.com/news/duke-street-bio-granted-approval-by-european-medicines-agency-to-launch-next 2024-09-25T20:23:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/duke-street-bio-granted-approval-by-european-medicines-agency-to-launch-next 2024-09-25T20:23:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-tagrisso-for-some-with-advanced-nsclc-cure-today 2024-09-25T20:22:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-tagrisso-for-some-with-advanced-nsclc-cure-today 2024-09-25T20:22:16+00:00 weekly 0.7 https://trial.medpath.com/news/inventiva-provides-a-corporate-update-and-reports-its-unaudited-2024-first-half-financial-results 2024-09-25T20:15:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inventiva-provides-a-corporate-update-and-reports-its-unaudited-2024-first-half-financial-results 2024-09-25T20:15:32+00:00 weekly 0.7 https://trial.medpath.com/news/immunization-roundup-fda-approves-flumist-updated-novavax-covid-19-vaccine 2024-09-25T19:47:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunization-roundup-fda-approves-flumist-updated-novavax-covid-19-vaccine 2024-09-25T19:47:16+00:00 weekly 0.7 https://trial.medpath.com/news/ema-to-discuss-pfizer-s-sickle-cell-drug-oxbryta-after-patient-deaths-endpoints-news 2024-09-25T19:38:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-to-discuss-pfizer-s-sickle-cell-drug-oxbryta-after-patient-deaths-endpoints-news 2024-09-25T19:38:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinicaltrials-eu-platform-rolled-out-across-europe 2024-09-25T19:15:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinicaltrials-eu-platform-rolled-out-across-europe 2024-09-25T19:15:04+00:00 weekly 0.7 https://trial.medpath.com/news/mesopher-cell-therapy-increases-2-year-rfs-rate-in-resected-pancreatic-cancer-by-50 2024-09-25T18:31:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mesopher-cell-therapy-increases-2-year-rfs-rate-in-resected-pancreatic-cancer-by-50 2024-09-25T18:31:15+00:00 weekly 0.7 https://trial.medpath.com/news/tcbp-announces-site-opening-of-guys-and-st-thomas-hospital-pr-newswire 2024-09-25T18:30:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tcbp-announces-site-opening-of-guys-and-st-thomas-hospital-pr-newswire 2024-09-25T18:30:37+00:00 weekly 0.7 https://trial.medpath.com/news/non-operative-management-of-rectal-cancer-does-not-worsen-distant-rfs 2024-09-25T18:15:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/non-operative-management-of-rectal-cancer-does-not-worsen-distant-rfs 2024-09-25T18:15:11+00:00 weekly 0.7 https://trial.medpath.com/news/galmed-publishes-results-from-aramchol-phase-3-open-label-part-in-hepatology-pr-newswire 2024-09-25T18:00:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/galmed-publishes-results-from-aramchol-phase-3-open-label-part-in-hepatology-pr-newswire 2024-09-25T18:00:30+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-may-reduce-opioid-overdoses-a-new-study-suggests-science-news 2024-09-25T17:59:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/semaglutide-may-reduce-opioid-overdoses-a-new-study-suggests-science-news 2024-09-25T17:59:18+00:00 weekly 0.7 https://trial.medpath.com/news/baptist-health-treats-first-liver-cancer-patients-with-histotripsy 2024-09-25T17:57:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/baptist-health-treats-first-liver-cancer-patients-with-histotripsy 2024-09-25T17:57:12+00:00 weekly 0.7 https://trial.medpath.com/news/acasti-announces-completion-of-patient-enrollment-in-globenewswire 2024-09-25T17:30:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acasti-announces-completion-of-patient-enrollment-in-globenewswire 2024-09-25T17:30:40+00:00 weekly 0.7 https://trial.medpath.com/news/promising-drug-combo-targets-aggressive-bladder-cancers-medical-xpress 2024-09-25T17:21:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promising-drug-combo-targets-aggressive-bladder-cancers-medical-xpress 2024-09-25T17:21:49+00:00 weekly 0.7 https://trial.medpath.com/news/ayuvis-incubated-at-hsc-receives-fda-fast-track-for-drug-preventing-preterm-infant-lung-disease 2024-09-25T17:13:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ayuvis-incubated-at-hsc-receives-fda-fast-track-for-drug-preventing-preterm-infant-lung-disease 2024-09-25T17:13:56+00:00 weekly 0.7 https://trial.medpath.com/news/uplizna-improved-outcomes-over-placebo-in-phase-3-trials-for-igg4-rd-myasthenia-gravis 2024-09-25T16:48:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uplizna-improved-outcomes-over-placebo-in-phase-3-trials-for-igg4-rd-myasthenia-gravis 2024-09-25T16:48:29+00:00 weekly 0.7 https://trial.medpath.com/news/fever-prevention-in-patients-with-acute-vascular-brain-injury-jama-network 2024-09-25T16:36:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fever-prevention-in-patients-with-acute-vascular-brain-injury-jama-network 2024-09-25T16:36:27+00:00 weekly 0.7 https://trial.medpath.com/news/q-a-promising-treatment-diagnosis-approaches-for-endometrial-cancer-healio 2024-09-25T16:24:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/q-a-promising-treatment-diagnosis-approaches-for-endometrial-cancer-healio 2024-09-25T16:24:26+00:00 weekly 0.7 https://trial.medpath.com/news/opm-announces-its-first-half-2024-results-and-provides-an-update-on-its-clinical-morningstar 2024-09-25T16:19:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/opm-announces-its-first-half-2024-results-and-provides-an-update-on-its-clinical-morningstar 2024-09-25T16:19:52+00:00 weekly 0.7 https://trial.medpath.com/news/why-do-obesity-drugs-seem-to-treat-so-many-other-ailments-nature 2024-09-25T16:10:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-do-obesity-drugs-seem-to-treat-so-many-other-ailments-nature 2024-09-25T16:10:18+00:00 weekly 0.7 https://trial.medpath.com/news/groundbreaking-trial-launches-for-everyone-with-ewing-sarcoma-cancer-news 2024-09-25T16:03:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/groundbreaking-trial-launches-for-everyone-with-ewing-sarcoma-cancer-news 2024-09-25T16:03:30+00:00 weekly 0.7 https://trial.medpath.com/news/phaxiam-provides-business-and-financial-update-for-the-first-half-of-2024-globenewswire 2024-09-25T15:56:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phaxiam-provides-business-and-financial-update-for-the-first-half-of-2024-globenewswire 2024-09-25T15:56:37+00:00 weekly 0.7 https://trial.medpath.com/news/lung-recruitment-before-surfactant-administration-in-extremely-preterm-neonates-jama-network 2024-09-25T15:30:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lung-recruitment-before-surfactant-administration-in-extremely-preterm-neonates-jama-network 2024-09-25T15:30:19+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-and-opioid-overdose-risk-in-patients-with-type-2-diabetes-and-opioid-use-disorder 2024-09-25T15:30:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/semaglutide-and-opioid-overdose-risk-in-patients-with-type-2-diabetes-and-opioid-use-disorder 2024-09-25T15:30:15+00:00 weekly 0.7 https://trial.medpath.com/news/could-ozempic-help-prevent-opioid-overdoses 2024-09-25T15:09:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-ozempic-help-prevent-opioid-overdoses 2024-09-25T15:09:58+00:00 weekly 0.7 https://trial.medpath.com/news/in-bronchiectasis-cathepsin-c-inhibitor-reduces-exacerbation-risk-pulmonology-advisor 2024-09-25T15:05:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in-bronchiectasis-cathepsin-c-inhibitor-reduces-exacerbation-risk-pulmonology-advisor 2024-09-25T15:05:58+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-may-not-benefit-all-gastroesophageal-cancer-patients-fda-staff-says 2024-09-25T14:48:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-may-not-benefit-all-gastroesophageal-cancer-patients-fda-staff-says 2024-09-25T14:48:47+00:00 weekly 0.7 https://trial.medpath.com/news/combination-treatment-aids-immunotherapies-to-target-non-responsive-lung-cancer-tumors 2024-09-25T14:47:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/combination-treatment-aids-immunotherapies-to-target-non-responsive-lung-cancer-tumors 2024-09-25T14:47:34+00:00 weekly 0.7 https://trial.medpath.com/news/spinogenix-announces-launch-of-a-phase-2-clinical-trial-evaluating-spg302-for-the-morningstar 2024-09-25T14:21:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spinogenix-announces-launch-of-a-phase-2-clinical-trial-evaluating-spg302-for-the-morningstar 2024-09-25T14:21:08+00:00 weekly 0.7 https://trial.medpath.com/news/shield-therapeutics-announces-promising-paediatric-trial-results-halifax-market-news 2024-09-25T14:00:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shield-therapeutics-announces-promising-paediatric-trial-results-halifax-market-news 2024-09-25T14:00:54+00:00 weekly 0.7 https://trial.medpath.com/news/fda-considers-narrowing-label-of-pd-1-drugs-in-stomach-cancer-ahead-of-adcomm-meeting 2024-09-25T13:47:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-considers-narrowing-label-of-pd-1-drugs-in-stomach-cancer-ahead-of-adcomm-meeting 2024-09-25T13:47:39+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-keytruda-combo-fails-in-phase-iii-colorectal-cancer-study-biospace 2024-09-25T13:11:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-s-keytruda-combo-fails-in-phase-iii-colorectal-cancer-study-biospace 2024-09-25T13:11:54+00:00 weekly 0.7 https://trial.medpath.com/news/golfers-against-cancer-denver-funds-cu-cancer-center-research-on-pediatric-cancer 2024-09-25T12:39:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/golfers-against-cancer-denver-funds-cu-cancer-center-research-on-pediatric-cancer 2024-09-25T12:39:25+00:00 weekly 0.7 https://trial.medpath.com/news/daehan-nupharm-launches-a-new-influenza-treatment-kbr 2024-09-25T12:35:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/daehan-nupharm-launches-a-new-influenza-treatment-kbr 2024-09-25T12:35:58+00:00 weekly 0.7 https://trial.medpath.com/news/ferring-presents-efficacy-and-safety-data-from-two-phase-3-studies-for-investigational 2024-09-25T12:31:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ferring-presents-efficacy-and-safety-data-from-two-phase-3-studies-for-investigational 2024-09-25T12:31:08+00:00 weekly 0.7 https://trial.medpath.com/news/heron-therapeutics-announces-fda-approval-of-the-prior-approval-supplement-application 2024-09-25T12:03:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/heron-therapeutics-announces-fda-approval-of-the-prior-approval-supplement-application 2024-09-25T12:03:05+00:00 weekly 0.7 https://trial.medpath.com/news/durect-corporation-announces-phase-3-registrational-trial-design-for-larsucosterol-in 2024-09-25T12:01:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/durect-corporation-announces-phase-3-registrational-trial-design-for-larsucosterol-in 2024-09-25T12:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/new-research-advances-understanding-of-multiple-myeloma-precursor-diseases-mgus-and-smm 2024-09-25T11:25:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-research-advances-understanding-of-multiple-myeloma-precursor-diseases-mgus-and-smm 2024-09-25T11:25:02+00:00 weekly 0.7 https://trial.medpath.com/news/merck-provides-update-on-phase-3-keyform-007-trial-evaluating-investigational-fixed 2024-09-25T11:20:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-provides-update-on-phase-3-keyform-007-trial-evaluating-investigational-fixed 2024-09-25T11:20:14+00:00 weekly 0.7 https://trial.medpath.com/news/kyowa-kirin-announces-top-line-data-from-rocatinlimab-phase-3-rocket-horizon-trial 2024-09-25T11:00:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kyowa-kirin-announces-top-line-data-from-rocatinlimab-phase-3-rocket-horizon-trial 2024-09-25T11:00:51+00:00 weekly 0.7 https://trial.medpath.com/news/novo-grilled-by-senate-phrma-s-ira-win-and-bms-karxt-awaits-approval-biospace 2024-09-25T10:47:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-grilled-by-senate-phrma-s-ira-win-and-bms-karxt-awaits-approval-biospace 2024-09-25T10:47:08+00:00 weekly 0.7 https://trial.medpath.com/news/sample-size-recalculation-in-three-stage-clinical-trials-and-its-evaluation 2024-09-25T10:39:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sample-size-recalculation-in-three-stage-clinical-trials-and-its-evaluation 2024-09-25T10:39:55+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-s-amgn-drugs-show-promise-in-phase-3-trials-tipranks-com 2024-09-25T10:17:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-s-amgn-drugs-show-promise-in-phase-3-trials-tipranks-com 2024-09-25T10:17:52+00:00 weekly 0.7 https://trial.medpath.com/news/reducing-barriers-to-glucose-monitoring-the-regulatory-review 2024-09-25T10:13:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reducing-barriers-to-glucose-monitoring-the-regulatory-review 2024-09-25T10:13:19+00:00 weekly 0.7 https://trial.medpath.com/news/genespire-raises-us-52m-in-series-b-round-european-biotechnology-magazine 2024-09-25T09:38:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genespire-raises-us-52m-in-series-b-round-european-biotechnology-magazine 2024-09-25T09:38:44+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-disentangles-immune-issues-and-boosts-anti-cancer-effect-of-bone-marrow 2024-09-25T09:23:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-disentangles-immune-issues-and-boosts-anti-cancer-effect-of-bone-marrow 2024-09-25T09:23:54+00:00 weekly 0.7 https://trial.medpath.com/news/experimental-nasal-spray-might-ward-off-multiple-viruses 2024-09-25T09:09:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experimental-nasal-spray-might-ward-off-multiple-viruses 2024-09-25T09:09:30+00:00 weekly 0.7 https://trial.medpath.com/news/mayo-clinic-expert-outlines-future-of-pharmacogenomics-and-precision-medicine-in-oncology-care 2024-09-25T08:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mayo-clinic-expert-outlines-future-of-pharmacogenomics-and-precision-medicine-in-oncology-care 2024-09-25T08:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-england-fast-tracks-new-life-extending-blood-cancer-treatment-conservative-post 2024-09-25T07:24:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nhs-england-fast-tracks-new-life-extending-blood-cancer-treatment-conservative-post 2024-09-25T07:24:45+00:00 weekly 0.7 https://trial.medpath.com/news/biocina-partners-with-engeneic-to-manufacture-novel-nanocell-cancer-therapy 2024-09-25T06:50:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biocina-partners-with-engeneic-to-manufacture-novel-nanocell-cancer-therapy 2024-09-25T06:50:06+00:00 weekly 0.7 https://trial.medpath.com/news/the-last-day-of-trading-in-diamyd-medical-s-warrants-of-series-to-3-is-today 2024-09-25T06:42:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-last-day-of-trading-in-diamyd-medical-s-warrants-of-series-to-3-is-today 2024-09-25T06:42:34+00:00 weekly 0.7 https://trial.medpath.com/news/shield-therapeutics-hails-paediatric-phase-iii-study-success-aim-stx-otcqx-shief 2024-09-25T06:41:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shield-therapeutics-hails-paediatric-phase-iii-study-success-aim-stx-otcqx-shief 2024-09-25T06:41:28+00:00 weekly 0.7 https://trial.medpath.com/news/epigenetic-drug-development-sees-record-342m-series-a-funding-surge-in-early-2024 2024-09-25T06:38:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/epigenetic-drug-development-sees-record-342m-series-a-funding-surge-in-early-2024 2024-09-25T06:38:23+00:00 weekly 0.7 https://trial.medpath.com/news/capricor-therapeutics-announces-intent-to-file-biologics-license-application-for-full-biospace 2024-09-25T06:32:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/capricor-therapeutics-announces-intent-to-file-biologics-license-application-for-full-biospace 2024-09-25T06:32:22+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-enrolled-in-phase-i-program-in-stk11-mutant-non-small-cell-lung-cancer-at 2024-09-25T06:32:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-enrolled-in-phase-i-program-in-stk11-mutant-non-small-cell-lung-cancer-at 2024-09-25T06:32:22+00:00 weekly 0.7 https://trial.medpath.com/news/steritas-pediatric-glucocorticoid-toxicity-index-applied-by-alder-hey-children-s-nhs 2024-09-25T06:26:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/steritas-pediatric-glucocorticoid-toxicity-index-applied-by-alder-hey-children-s-nhs 2024-09-25T06:26:33+00:00 weekly 0.7 https://trial.medpath.com/news/convergent-therapeutics-announces-first-patient-treated-in-phase-ii-clinical-trial-pr-newswire 2024-09-25T06:05:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/convergent-therapeutics-announces-first-patient-treated-in-phase-ii-clinical-trial-pr-newswire 2024-09-25T06:05:53+00:00 weekly 0.7 https://trial.medpath.com/news/barinthus-bio-initiates-phase-1-clinical-trial-of-vtp-1000-for-the-treatment-of-celiac-disease 2024-09-25T05:59:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/barinthus-bio-initiates-phase-1-clinical-trial-of-vtp-1000-for-the-treatment-of-celiac-disease 2024-09-25T05:59:45+00:00 weekly 0.7 https://trial.medpath.com/news/media-update-eadv-new-data-reinforce-sanofi-s-innovative-approach-and-leadership 2024-09-25T05:52:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/media-update-eadv-new-data-reinforce-sanofi-s-innovative-approach-and-leadership 2024-09-25T05:52:59+00:00 weekly 0.7 https://trial.medpath.com/news/new-galderma-data-demonstrating-nemolizumab-s-long-term-efficacy-and-safety-in-atopic 2024-09-25T05:40:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-galderma-data-demonstrating-nemolizumab-s-long-term-efficacy-and-safety-in-atopic 2024-09-25T05:40:53+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-reports-success-for-eczema-and-myasthenia-gravis-treatments-stat-news 2024-09-25T05:12:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-reports-success-for-eczema-and-myasthenia-gravis-treatments-stat-news 2024-09-25T05:12:50+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-moffitt-cancer-center-partner-firefly-neuroscience-advances-ai-tech-more 2024-09-25T05:00:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-moffitt-cancer-center-partner-firefly-neuroscience-advances-ai-tech-more 2024-09-25T05:00:08+00:00 weekly 0.7 https://trial.medpath.com/news/nabp-prepares-pharmacies-for-critical-dscsa-compliance-deadline-in-november-2024 2024-09-25T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nabp-prepares-pharmacies-for-critical-dscsa-compliance-deadline-in-november-2024 2024-09-25T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/junshi-biosciences-announces-european-commission-approval-for-marketing-of-toripalimab 2024-09-25T04:28:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/junshi-biosciences-announces-european-commission-approval-for-marketing-of-toripalimab 2024-09-25T04:28:59+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-voluntarily-withdraws-all-lots-of-sickle-cell-disease-treatment-oxbryta-voxelotor-from-worldwide-markets 2024-09-25T04:09:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-voluntarily-withdraws-all-lots-of-sickle-cell-disease-treatment-oxbryta-voxelotor-from-worldwide-markets 2024-09-25T04:09:06+00:00 weekly 0.7 https://trial.medpath.com/news/sprim-pro-announces-a-novel-and-validated-approach-for-monitoring-infant-growth-from 2024-09-25T03:58:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sprim-pro-announces-a-novel-and-validated-approach-for-monitoring-infant-growth-from 2024-09-25T03:58:34+00:00 weekly 0.7 https://trial.medpath.com/news/spine-biopharma-inc-announces-completion-of-enrollment-for-phase-3-clinical-trial-of-sb 2024-09-25T03:13:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spine-biopharma-inc-announces-completion-of-enrollment-for-phase-3-clinical-trial-of-sb 2024-09-25T03:13:01+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-stock-slips-3-following-phase-3-data-for-rocatinlimab-uplizna-seeking-alpha 2024-09-25T01:47:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-stock-slips-3-following-phase-3-data-for-rocatinlimab-uplizna-seeking-alpha 2024-09-25T01:47:06+00:00 weekly 0.7 https://trial.medpath.com/news/fda-cracks-down-on-counterfeit-ozempic-and-mounjaro-as-illegal-compounding-surges 2024-09-25T01:32:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-cracks-down-on-counterfeit-ozempic-and-mounjaro-as-illegal-compounding-surges 2024-09-25T01:32:09+00:00 weekly 0.7 https://trial.medpath.com/news/epineuron-announces-health-canada-approval-of-the-peripulsetm-system-for-nerve-regeneration 2024-09-25T01:27:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/epineuron-announces-health-canada-approval-of-the-peripulsetm-system-for-nerve-regeneration 2024-09-25T01:27:53+00:00 weekly 0.7 https://trial.medpath.com/news/enalare-receives-fda-clearance-to-initiate-the-first-phase-1-clinical-study-of-ena-001-to 2024-09-25T01:27:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enalare-receives-fda-clearance-to-initiate-the-first-phase-1-clinical-study-of-ena-001-to 2024-09-25T01:27:51+00:00 weekly 0.7 https://trial.medpath.com/news/ground-breaking-covid-19-antiviral-treatment-trial-opens-to-recruitment-nihr 2024-09-25T00:25:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ground-breaking-covid-19-antiviral-treatment-trial-opens-to-recruitment-nihr 2024-09-25T00:25:14+00:00 weekly 0.7 https://trial.medpath.com/news/piper-sandler-maintains-overweight-rating-on-acelyrin-shares 2024-09-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/piper-sandler-maintains-overweight-rating-on-acelyrin-shares 2024-09-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/caribou-biosciences-to-present-preclinical-data-on-cb-010-for-lupus-at-acr-convergence-2024 2024-09-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/caribou-biosciences-to-present-preclinical-data-on-cb-010-for-lupus-at-acr-convergence-2024 2024-09-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-helps-fredon-nj-man-find-leukemia-remission-hackensack-meridian-health 2024-09-24T23:55:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-helps-fredon-nj-man-find-leukemia-remission-hackensack-meridian-health 2024-09-24T23:55:04+00:00 weekly 0.7 https://trial.medpath.com/news/rheacell-announces-fda-approval-for-phase-3-study-in-refractory-non-curable-cvu-prleap 2024-09-24T23:07:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rheacell-announces-fda-approval-for-phase-3-study-in-refractory-non-curable-cvu-prleap 2024-09-24T23:07:14+00:00 weekly 0.7 https://trial.medpath.com/news/regulatory-approvals-and-governance-nihr 2024-09-24T22:19:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regulatory-approvals-and-governance-nihr 2024-09-24T22:19:40+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-pharma-secures-25m-loan-eyes-fda-drug-approval-investing-com 2024-09-24T21:24:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/urogen-pharma-secures-25m-loan-eyes-fda-drug-approval-investing-com 2024-09-24T21:24:39+00:00 weekly 0.7 https://trial.medpath.com/news/marstacimab-recommended-for-eu-approval-for-hemophilia-a-and-b 2024-09-24T21:07:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/marstacimab-recommended-for-eu-approval-for-hemophilia-a-and-b 2024-09-24T21:07:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-gives-lupin-approval-for-bumetanide-injection-drug-store-news 2024-09-24T20:39:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-gives-lupin-approval-for-bumetanide-injection-drug-store-news 2024-09-24T20:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/a-clinical-trial-has-halted-progression-of-merkel-cell-carcinoma-and-allowed-me-to-pursue 2024-09-24T20:34:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-clinical-trial-has-halted-progression-of-merkel-cell-carcinoma-and-allowed-me-to-pursue 2024-09-24T20:34:41+00:00 weekly 0.7 https://trial.medpath.com/news/successful-clinical-trial-for-antibacterial-implants-by-aap-implantate-ag-webdisclosure 2024-09-24T20:23:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/successful-clinical-trial-for-antibacterial-implants-by-aap-implantate-ag-webdisclosure 2024-09-24T20:23:53+00:00 weekly 0.7 https://trial.medpath.com/news/tepezza-r-teprotumumab-receives-approval-in-japan-for-the-treatment 2024-09-24T20:19:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tepezza-r-teprotumumab-receives-approval-in-japan-for-the-treatment 2024-09-24T20:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/enfortumab-vedotin-combo-earns-japanese-approval-for-urothelial-carcinoma 2024-09-24T20:10:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enfortumab-vedotin-combo-earns-japanese-approval-for-urothelial-carcinoma 2024-09-24T20:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/umass-chan-researchers-develop-dual-therapeutic-that-holds-promise-as-pancreatic-cancer 2024-09-24T19:59:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/umass-chan-researchers-develop-dual-therapeutic-that-holds-promise-as-pancreatic-cancer 2024-09-24T19:59:21+00:00 weekly 0.7 https://trial.medpath.com/news/dod-awards-pitt-100m-for-trauma-trials-upmc 2024-09-24T19:32:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dod-awards-pitt-100m-for-trauma-trials-upmc 2024-09-24T19:32:55+00:00 weekly 0.7 https://trial.medpath.com/news/new-data-published-in-jaaos-demonstrates-breakthrough-therapy-zetafuse-yahoo-finance 2024-09-24T19:20:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-data-published-in-jaaos-demonstrates-breakthrough-therapy-zetafuse-yahoo-finance 2024-09-24T19:20:54+00:00 weekly 0.7 https://trial.medpath.com/news/eshoo-bill-to-improve-pediatric-drugs-passes-house-unanimously 2024-09-24T19:16:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eshoo-bill-to-improve-pediatric-drugs-passes-house-unanimously 2024-09-24T19:16:02+00:00 weekly 0.7 https://trial.medpath.com/news/nxera-pharma-receives-approval-of-quviviq-daridorexant-25-and-50-mg-in-japan-for-the 2024-09-24T19:13:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nxera-pharma-receives-approval-of-quviviq-daridorexant-25-and-50-mg-in-japan-for-the 2024-09-24T19:13:11+00:00 weekly 0.7 https://trial.medpath.com/news/iomab-b-leads-to-more-durable-responses-vs-allohct-in-aml-treatment 2024-09-24T19:12:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iomab-b-leads-to-more-durable-responses-vs-allohct-in-aml-treatment 2024-09-24T19:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/cutting-edge-multi-arm-octopus-trial-continues-to-progress-well-neurologylive 2024-09-24T19:09:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cutting-edge-multi-arm-octopus-trial-continues-to-progress-well-neurologylive 2024-09-24T19:09:02+00:00 weekly 0.7 https://trial.medpath.com/news/recon-japan-approves-lilly-s-alzheimer-s-drug-mhra-seeks-applicants-for-ai-airlock 2024-09-24T19:07:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recon-japan-approves-lilly-s-alzheimer-s-drug-mhra-seeks-applicants-for-ai-airlock 2024-09-24T19:07:05+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-research-network-nihr 2024-09-24T18:55:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-research-network-nihr 2024-09-24T18:55:01+00:00 weekly 0.7 https://trial.medpath.com/news/lipidor-ab-announces-first-patient-enrolled-in-phase-iii-study-of-akp02g2-for-topical 2024-09-24T18:49:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lipidor-ab-announces-first-patient-enrolled-in-phase-iii-study-of-akp02g2-for-topical 2024-09-24T18:49:14+00:00 weekly 0.7 https://trial.medpath.com/news/hesperos-provides-support-for-an-investigational-product-for-a-phase-ii-clinical-trial-with-its 2024-09-24T18:39:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hesperos-provides-support-for-an-investigational-product-for-a-phase-ii-clinical-trial-with-its 2024-09-24T18:39:28+00:00 weekly 0.7 https://trial.medpath.com/news/the-odyssey-of-homer-comparative-effectiveness-research-on-medication-for-opioid-use 2024-09-24T18:30:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-odyssey-of-homer-comparative-effectiveness-research-on-medication-for-opioid-use 2024-09-24T18:30:56+00:00 weekly 0.7 https://trial.medpath.com/news/partiqol-trial-proton-therapy-vs-imrt-for-localized-prostate-cancer-jason-efstathiou 2024-09-24T18:14:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/partiqol-trial-proton-therapy-vs-imrt-for-localized-prostate-cancer-jason-efstathiou 2024-09-24T18:14:23+00:00 weekly 0.7 https://trial.medpath.com/news/zkr-orthopedics-performs-first-u-s-patella-lift-procedure-initiating-fda-trial-biospace 2024-09-24T18:12:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zkr-orthopedics-performs-first-u-s-patella-lift-procedure-initiating-fda-trial-biospace 2024-09-24T18:12:42+00:00 weekly 0.7 https://trial.medpath.com/news/b-braun-medical-receives-fda-clearance-for-introcan-safety-r-2-deep-access-iv-catheter 2024-09-24T18:12:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/b-braun-medical-receives-fda-clearance-for-introcan-safety-r-2-deep-access-iv-catheter 2024-09-24T18:12:10+00:00 weekly 0.7 https://trial.medpath.com/news/the-role-of-surgery-continues-to-evolve-in-seminoma-urology-times 2024-09-24T18:04:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-role-of-surgery-continues-to-evolve-in-seminoma-urology-times 2024-09-24T18:04:54+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-publish-critical-examination-of-new-brain-tumor-drug-medical-xpress 2024-09-24T17:54:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/researchers-publish-critical-examination-of-new-brain-tumor-drug-medical-xpress 2024-09-24T17:54:06+00:00 weekly 0.7 https://trial.medpath.com/news/georgiamune-announces-first-participant-dosed-in-first-in-class-phase-1-healthy 2024-09-24T17:51:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/georgiamune-announces-first-participant-dosed-in-first-in-class-phase-1-healthy 2024-09-24T17:51:27+00:00 weekly 0.7 https://trial.medpath.com/news/aurinia-announces-japan-approval-of-lupkynis-r-voclosporin-to-treat-lupus-nephritis 2024-09-24T17:50:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aurinia-announces-japan-approval-of-lupkynis-r-voclosporin-to-treat-lupus-nephritis 2024-09-24T17:50:59+00:00 weekly 0.7 https://trial.medpath.com/news/senseonics-stock-down-despite-new-fda-approval-for-eversense-365-yahoo-finance 2024-09-24T17:47:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/senseonics-stock-down-despite-new-fda-approval-for-eversense-365-yahoo-finance 2024-09-24T17:47:35+00:00 weekly 0.7 https://trial.medpath.com/news/transgene-to-report-major-clinical-data-before-the-end-of-2024-confirmed-financial 2024-09-24T17:38:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/transgene-to-report-major-clinical-data-before-the-end-of-2024-confirmed-financial 2024-09-24T17:38:02+00:00 weekly 0.7 https://trial.medpath.com/news/inexpensive-drug-can-prevent-cerebral-palsy-in-premature-babies-cochrane 2024-09-24T17:26:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inexpensive-drug-can-prevent-cerebral-palsy-in-premature-babies-cochrane 2024-09-24T17:26:16+00:00 weekly 0.7 https://trial.medpath.com/news/renal-cancer-clinical-trial-pipeline-appears-robust-with-75-key-pharma-companies 2024-09-24T17:17:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/renal-cancer-clinical-trial-pipeline-appears-robust-with-75-key-pharma-companies 2024-09-24T17:17:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-roflumilast-s-snda-to-treat-scalp-and-body-psoriasis-in-adolescents-adults 2024-09-24T17:07:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-roflumilast-s-snda-to-treat-scalp-and-body-psoriasis-in-adolescents-adults 2024-09-24T17:07:58+00:00 weekly 0.7 https://trial.medpath.com/news/cerapedics-i-factor-p-15-peptide-enhanced-bone-graft-a-trusted-choice-ortho-spine-news 2024-09-24T16:50:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cerapedics-i-factor-p-15-peptide-enhanced-bone-graft-a-trusted-choice-ortho-spine-news 2024-09-24T16:50:06+00:00 weekly 0.7 https://trial.medpath.com/news/clene-granted-in-person-fda-meeting-on-cnm-au8-for-als-als-news-today 2024-09-24T16:17:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clene-granted-in-person-fda-meeting-on-cnm-au8-for-als-als-news-today 2024-09-24T16:17:55+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-s-kisunlatm-donanemab-azbt-approved-in-japan-for-the-treatment-of-early-pr-newswire 2024-09-24T16:00:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lilly-s-kisunlatm-donanemab-azbt-approved-in-japan-for-the-treatment-of-early-pr-newswire 2024-09-24T16:00:54+00:00 weekly 0.7 https://trial.medpath.com/news/re-cognition-health-usa-achieves-gcsa-clinical-trial-site-certification-contract-pharma 2024-09-24T15:45:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/re-cognition-health-usa-achieves-gcsa-clinical-trial-site-certification-contract-pharma 2024-09-24T15:45:43+00:00 weekly 0.7 https://trial.medpath.com/news/enrollment-complete-of-phase-2b-of-siglec-study-to-assess-safety-and-efficacy-of-avd-104 2024-09-24T15:14:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enrollment-complete-of-phase-2b-of-siglec-study-to-assess-safety-and-efficacy-of-avd-104 2024-09-24T15:14:04+00:00 weekly 0.7 https://trial.medpath.com/news/new-weight-loss-biotech-metsera-stuns-with-7-5-weight-loss-few-side-effects 2024-09-24T15:08:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-weight-loss-biotech-metsera-stuns-with-7-5-weight-loss-few-side-effects 2024-09-24T15:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/nevro-wins-fda-nod-for-ai-driven-spinal-cord-stimulation-tech-massdevice 2024-09-24T15:04:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nevro-wins-fda-nod-for-ai-driven-spinal-cord-stimulation-tech-massdevice 2024-09-24T15:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/ainos-spotlighted-in-water-tower-research-report-on-veldona-clinical-study-for-stock-titan 2024-09-24T15:03:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ainos-spotlighted-in-water-tower-research-report-on-veldona-clinical-study-for-stock-titan 2024-09-24T15:03:42+00:00 weekly 0.7 https://trial.medpath.com/news/neurosense-therapeutics-granted-key-u-s-patent-for-novel-primec-formulation-its-lead 2024-09-24T14:46:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurosense-therapeutics-granted-key-u-s-patent-for-novel-primec-formulation-its-lead 2024-09-24T14:46:58+00:00 weekly 0.7 https://trial.medpath.com/news/alxn2220-for-attr-amyloidosis-with-cardiomyopathy-granted-fast-track-designation 2024-09-24T14:46:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alxn2220-for-attr-amyloidosis-with-cardiomyopathy-granted-fast-track-designation 2024-09-24T14:46:50+00:00 weekly 0.7 https://trial.medpath.com/news/combination-targeted-therapy-produces-durable-remissions-in-some-patients-the-asco-post 2024-09-24T14:30:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/combination-targeted-therapy-produces-durable-remissions-in-some-patients-the-asco-post 2024-09-24T14:30:19+00:00 weekly 0.7 https://trial.medpath.com/news/nomic-r-and-parker-institute-for-cancer-immunotherapy-pici-launch-large-scale-protein 2024-09-24T13:45:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nomic-r-and-parker-institute-for-cancer-immunotherapy-pici-launch-large-scale-protein 2024-09-24T13:45:19+00:00 weekly 0.7 https://trial.medpath.com/news/china-medical-system-new-drug-application-for-vitiligo-indication-of-ruxolitinib-phosphate 2024-09-24T13:39:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/china-medical-system-new-drug-application-for-vitiligo-indication-of-ruxolitinib-phosphate 2024-09-24T13:39:28+00:00 weekly 0.7 https://trial.medpath.com/news/cardiol-therapeutics-reaches-target-enrollment-for-phase-ii-acute-myocarditis-trial 2024-09-24T13:13:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiol-therapeutics-reaches-target-enrollment-for-phase-ii-acute-myocarditis-trial 2024-09-24T13:13:16+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-immunotherapy-for-dmmr-and-pmmr-colorectal-cancers-nature 2024-09-24T13:12:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-immunotherapy-for-dmmr-and-pmmr-colorectal-cancers-nature 2024-09-24T13:12:25+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-results-show-low-intensity-therapy-can-achieve-positive-outcomes-for-certain 2024-09-24T13:01:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-results-show-low-intensity-therapy-can-achieve-positive-outcomes-for-certain 2024-09-24T13:01:12+00:00 weekly 0.7 https://trial.medpath.com/news/synergia-implants-first-patients-with-neurostimulator-for-epilepsy-treatment 2024-09-24T12:53:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/synergia-implants-first-patients-with-neurostimulator-for-epilepsy-treatment 2024-09-24T12:53:46+00:00 weekly 0.7 https://trial.medpath.com/news/low-intensity-repetitive-transcranial-magnetic-stimulation-enhances-myelin-repair-in-pre 2024-09-24T12:50:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/low-intensity-repetitive-transcranial-magnetic-stimulation-enhances-myelin-repair-in-pre 2024-09-24T12:50:50+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-sciences-announces-completion-of-an-interim-safety-review-of-oral-simufilam-on 2024-09-24T12:41:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cassava-sciences-announces-completion-of-an-interim-safety-review-of-oral-simufilam-on 2024-09-24T12:41:41+00:00 weekly 0.7 https://trial.medpath.com/news/psychedelic-therapies-are-coming-to-europe-but-face-barriers-before-reaching-patients 2024-09-24T12:39:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psychedelic-therapies-are-coming-to-europe-but-face-barriers-before-reaching-patients 2024-09-24T12:39:02+00:00 weekly 0.7 https://trial.medpath.com/news/enlivex-announces-positive-dsmb-recommendation-to-initiate-globenewswire 2024-09-24T12:36:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enlivex-announces-positive-dsmb-recommendation-to-initiate-globenewswire 2024-09-24T12:36:23+00:00 weekly 0.7 https://trial.medpath.com/news/cytodyn-announces-preliminary-findings-in-study-with-smc-laboratories 2024-09-24T12:30:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytodyn-announces-preliminary-findings-in-study-with-smc-laboratories 2024-09-24T12:30:46+00:00 weekly 0.7 https://trial.medpath.com/news/aurion-biotech-launches-vyznova-r-neltependocel-in-japan-for-the-treatment-of-bullous 2024-09-24T12:28:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aurion-biotech-launches-vyznova-r-neltependocel-in-japan-for-the-treatment-of-bullous 2024-09-24T12:28:06+00:00 weekly 0.7 https://trial.medpath.com/news/ksq-therapeutics-announces-fda-clearance-of-ind-application-for-ksq-004ex-a-crispr 2024-09-24T12:23:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ksq-therapeutics-announces-fda-clearance-of-ind-application-for-ksq-004ex-a-crispr 2024-09-24T12:23:20+00:00 weekly 0.7 https://trial.medpath.com/news/cpec-phase-ii-is-going-to-start-finance-minister-aaj-news 2024-09-24T12:17:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cpec-phase-ii-is-going-to-start-finance-minister-aaj-news 2024-09-24T12:17:03+00:00 weekly 0.7 https://trial.medpath.com/news/unity-biotechnology-to-host-in-person-ophthalmology-day-in-new-york-on-tuesday 2024-09-24T12:12:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unity-biotechnology-to-host-in-person-ophthalmology-day-in-new-york-on-tuesday 2024-09-24T12:12:27+00:00 weekly 0.7 https://trial.medpath.com/news/univo-irb-launches-canadian-research-ethics-board-review-services-for-clinical-trials-in 2024-09-24T12:11:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/univo-irb-launches-canadian-research-ethics-board-review-services-for-clinical-trials-in 2024-09-24T12:11:54+00:00 weekly 0.7 https://trial.medpath.com/news/silexion-therapeutics-announces-significant-new-data-from-phase-2-trial-of-lodertm-in 2024-09-24T11:48:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/silexion-therapeutics-announces-significant-new-data-from-phase-2-trial-of-lodertm-in 2024-09-24T11:48:30+00:00 weekly 0.7 https://trial.medpath.com/news/zevra-therapeutics-to-present-top-line-data-from-the-phase-2-clinical-trial-of-kp1077-for 2024-09-24T11:48:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zevra-therapeutics-to-present-top-line-data-from-the-phase-2-clinical-trial-of-kp1077-for 2024-09-24T11:48:24+00:00 weekly 0.7 https://trial.medpath.com/news/wave-life-sciences-announces-positive-interim-data-from-forward-53-clinical-trial 2024-09-24T11:33:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wave-life-sciences-announces-positive-interim-data-from-forward-53-clinical-trial 2024-09-24T11:33:10+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-ucb-get-the-lupus-data-they-ve-waited-two-decades-for-biopharma-dive 2024-09-24T11:08:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biogen-ucb-get-the-lupus-data-they-ve-waited-two-decades-for-biopharma-dive 2024-09-24T11:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/united-therapeutics-to-feature-clinical-data-across-its-commercial-and-development 2024-09-24T11:04:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/united-therapeutics-to-feature-clinical-data-across-its-commercial-and-development 2024-09-24T11:04:16+00:00 weekly 0.7 https://trial.medpath.com/news/mre-and-te-show-limited-accuracy-in-detecting-advanced-liver-fibrosis-in-pediatric-masld-patients 2024-09-24T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mre-and-te-show-limited-accuracy-in-detecting-advanced-liver-fibrosis-in-pediatric-masld-patients 2024-09-24T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-funding-to-better-understand-causes-of-rare-cancers-and-their-responses-to-targeted-therapy 2024-09-24T10:57:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-funding-to-better-understand-causes-of-rare-cancers-and-their-responses-to-targeted-therapy 2024-09-24T10:57:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-cluster-randomized-study-of-technology-assisted-health-coaching-for-weight 2024-09-24T10:12:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-cluster-randomized-study-of-technology-assisted-health-coaching-for-weight 2024-09-24T10:12:07+00:00 weekly 0.7 https://trial.medpath.com/news/lsu-lcmc-health-cancer-center-experts-discuss-advances-in-research-and-goals-for-a 2024-09-24T10:02:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lsu-lcmc-health-cancer-center-experts-discuss-advances-in-research-and-goals-for-a 2024-09-24T10:02:24+00:00 weekly 0.7 https://trial.medpath.com/news/senate-confronts-novo-nordisk-over-semaglutide-pricing-demands-u-s-price-parity-with-europe 2024-09-24T09:46:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/senate-confronts-novo-nordisk-over-semaglutide-pricing-demands-u-s-price-parity-with-europe 2024-09-24T09:46:54+00:00 weekly 0.7 https://trial.medpath.com/news/popular-diabetes-drug-metformin-may-slow-aging-study-finds-cbs-news 2024-09-24T09:38:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/popular-diabetes-drug-metformin-may-slow-aging-study-finds-cbs-news 2024-09-24T09:38:36+00:00 weekly 0.7 https://trial.medpath.com/news/psilocybin-may-curb-mental-illness-that-leads-to-eating-disorders 2024-09-24T09:09:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psilocybin-may-curb-mental-illness-that-leads-to-eating-disorders 2024-09-24T09:09:27+00:00 weekly 0.7 https://trial.medpath.com/news/algotx-announces-last-patient-last-visit-in-international-phase-ii-trial-of-atx01-in-morningstar 2024-09-24T07:53:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/algotx-announces-last-patient-last-visit-in-international-phase-ii-trial-of-atx01-in-morningstar 2024-09-24T07:53:57+00:00 weekly 0.7 https://trial.medpath.com/news/experts-discuss-treatment-strategies-and-challenges-in-managing-chronic-gvhd-after-stem-cell-transplantation 2024-09-24T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-discuss-treatment-strategies-and-challenges-in-managing-chronic-gvhd-after-stem-cell-transplantation 2024-09-24T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/chugai-receives-approvals-for-additional-indication-of-evrysdi-in-pre-symptomatic-spinal 2024-09-24T06:38:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chugai-receives-approvals-for-additional-indication-of-evrysdi-in-pre-symptomatic-spinal 2024-09-24T06:38:34+00:00 weekly 0.7 https://trial.medpath.com/news/medicare-drug-price-negotiations-pose-complex-challenges-for-community-oncology-practices 2024-09-24T06:26:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicare-drug-price-negotiations-pose-complex-challenges-for-community-oncology-practices 2024-09-24T06:26:29+00:00 weekly 0.7 https://trial.medpath.com/news/why-industry-must-design-alzheimer-s-trials-to-include-people-with-down-syndrome 2024-09-24T06:14:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-industry-must-design-alzheimer-s-trials-to-include-people-with-down-syndrome 2024-09-24T06:14:40+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-s-menveo-meningococcal-vaccine-in-new-single-vial-fully-liquid-presentation-receives 2024-09-24T06:04:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-s-menveo-meningococcal-vaccine-in-new-single-vial-fully-liquid-presentation-receives 2024-09-24T06:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/nfl-legend-brett-favre-reveals-parkinson-s-disease-diagnosis-amid-congressional-testimony 2024-09-24T05:22:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nfl-legend-brett-favre-reveals-parkinson-s-disease-diagnosis-amid-congressional-testimony 2024-09-24T05:22:45+00:00 weekly 0.7 https://trial.medpath.com/news/basilea-initiates-clinical-phase-3-study-with-antifungal-globenewswire 2024-09-24T05:21:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/basilea-initiates-clinical-phase-3-study-with-antifungal-globenewswire 2024-09-24T05:21:19+00:00 weekly 0.7 https://trial.medpath.com/news/santhera-announces-acceptance-by-swissmedic-of-marketing-authorization-application-for 2024-09-24T05:10:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/santhera-announces-acceptance-by-swissmedic-of-marketing-authorization-application-for 2024-09-24T05:10:16+00:00 weekly 0.7 https://trial.medpath.com/news/opensafely-platform-revolutionizes-big-data-medical-research-with-enhanced-privacy-protection 2024-09-24T05:01:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/opensafely-platform-revolutionizes-big-data-medical-research-with-enhanced-privacy-protection 2024-09-24T05:01:50+00:00 weekly 0.7 https://trial.medpath.com/news/amr-accelerator-urges-long-term-funding-european-biotechnology-magazine 2024-09-24T04:11:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amr-accelerator-urges-long-term-funding-european-biotechnology-magazine 2024-09-24T04:11:22+00:00 weekly 0.7 https://trial.medpath.com/news/lighting-the-way-to-pain-relief-drug-discovery-news 2024-09-24T04:03:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lighting-the-way-to-pain-relief-drug-discovery-news 2024-09-24T04:03:47+00:00 weekly 0.7 https://trial.medpath.com/news/leading-neuro-oncologist-emphasizes-importance-of-proactive-mentorship-in-brain-cancer-research 2024-09-24T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leading-neuro-oncologist-emphasizes-importance-of-proactive-mentorship-in-brain-cancer-research 2024-09-24T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-pharmaceuticals-announces-data-presentations-on-tnx-102-sl-for-fibromyalgia-at 2024-09-24T03:56:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-announces-data-presentations-on-tnx-102-sl-for-fibromyalgia-at 2024-09-24T03:56:28+00:00 weekly 0.7 https://trial.medpath.com/news/new-model-identifies-cancer-patients-at-high-risk-for-er-visits-during-clinical-trials 2024-09-24T02:51:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-model-identifies-cancer-patients-at-high-risk-for-er-visits-during-clinical-trials 2024-09-24T02:51:43+00:00 weekly 0.7 https://trial.medpath.com/news/reconsidering-rems-mandate-may-improve-car-t-cell-therapy-accessibility 2024-09-24T02:04:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reconsidering-rems-mandate-may-improve-car-t-cell-therapy-accessibility 2024-09-24T02:04:14+00:00 weekly 0.7 https://trial.medpath.com/news/detecting-clear-cell-renal-cell-carcinoma-use-of-zr-89-girentuximab-pet-ct-imaging 2024-09-24T01:56:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/detecting-clear-cell-renal-cell-carcinoma-use-of-zr-89-girentuximab-pet-ct-imaging 2024-09-24T01:56:15+00:00 weekly 0.7 https://trial.medpath.com/news/south-korean-study-finds-fecal-microbiota-transplants-may-help-patients-with-dark-daily 2024-09-24T01:22:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/south-korean-study-finds-fecal-microbiota-transplants-may-help-patients-with-dark-daily 2024-09-24T01:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/neurosense-regains-compliance-with-nasdaq-minimum-bid-price-rule 2024-09-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurosense-regains-compliance-with-nasdaq-minimum-bid-price-rule 2024-09-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-unveils-tags-technology-revolutionary-multi-pathogen-detection-system-for-infectious-diseases 2024-09-23T23:17:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-unveils-tags-technology-revolutionary-multi-pathogen-detection-system-for-infectious-diseases 2024-09-23T23:17:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-leo-pharmas-filing-of-delgocitinib-cream-new-drug-application-for-the-treatment-of-chronic-hand-eczema 2024-09-23T23:09:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-leo-pharmas-filing-of-delgocitinib-cream-new-drug-application-for-the-treatment-of-chronic-hand-eczema 2024-09-23T23:09:08+00:00 weekly 0.7 https://trial.medpath.com/news/cenna-biosciences-receives-nih-nia-phase-ii-sbir-award-for-the-early-clinical-yahoo-finance 2024-09-23T22:53:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cenna-biosciences-receives-nih-nia-phase-ii-sbir-award-for-the-early-clinical-yahoo-finance 2024-09-23T22:53:14+00:00 weekly 0.7 https://trial.medpath.com/news/effectiveness-of-rimegepant-further-displayed-in-pooled-phase-3-analysis-neurologylive 2024-09-23T22:08:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effectiveness-of-rimegepant-further-displayed-in-pooled-phase-3-analysis-neurologylive 2024-09-23T22:08:36+00:00 weekly 0.7 https://trial.medpath.com/news/former-orphazyme-drug-arimoclomol-approved-by-fda-medwatch 2024-09-23T21:58:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/former-orphazyme-drug-arimoclomol-approved-by-fda-medwatch 2024-09-23T21:58:28+00:00 weekly 0.7 https://trial.medpath.com/news/vicebio-secures-100m-to-advance-rsv-and-hmpv-vaccine-combo-to-phase-i 2024-09-23T21:20:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vicebio-secures-100m-to-advance-rsv-and-hmpv-vaccine-combo-to-phase-i 2024-09-23T21:20:09+00:00 weekly 0.7